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Nuclear receptors (NRs) are ligand-activated transcription factors that regulate the 
expression of genes involved in all physiological activities. Disruption in NR function (e.g. 
mutations) can lead to a variety of diseases; making these receptors important targets for drug 
discovery. The ability to bind a broad range of ‘drug-like’ molecules also make these receptors 
attractive candidates for protein engineering, such that they can be engineered to bind novel small 
molecule ligands, for several applications. One application is the creation of potential molecular 
switches, tools that can be used for controlling gene expression.  
Gaining knowledge of specific molecular interactions that occur between a receptor and 
its ligand is of interest, as they contribute towards the activation or repression of target genes. The 
focus of this work has been to investigate the structural and functional relationships between the 
human vitamin D receptor (hVDR) and its ligands. To date, mutational assessments of the hVDR 
have focused on alanine scanning and residues typically lining the ligand binding pocket (LBP) 
that are involved in direct interactions with the ligand. A comprehensive analysis of the tolerance 
of these residues in the binding and activation of the receptor by its ligands has not been 
performed. Furthermore, residues not in contact with the ligand or that do not line the LBP may 
also play an important role in determining the activation profiles observed for NRs, and therefore 
need to be explored further. 
In order to engineer and use the hVDR in chemical complementation, a genetic selection 
system in which the survival of yeast is linked to the activation of a NR by an agonist, the hVDR 
gene was isolated from cDNA. To gain insight into how chemical and physical changes within 
the ligand binding domain (LBD) affect receptor-ligand interactions, libraries of hVDR variants 
exploring the role and tolerance of hVDR residues were created. To develop a comprehensive 
mutational analysis while also engineering the hVDR to bind a novel small molecule ligand, a 
rational and a random mutagenic approach were used to create the libraries. A variant, 
 xvi
hVDRC410Y, that displayed enhanced activity with lithocholic acid (LCA), a known hVDR 
ligand, and novel activation with cholecalciferol (chole), a precursor of the hVDR’s natural 
ligand known not to activate the wild-type hVDR, was discovered.  
The presence of a tyrosine at the C410 position resulting in novel activation profiles with 
both LCA and chole, and the fact that this residue does not line the hVDR’s LBP led to interest in 
determining whether a physical or chemical property of the residue was responsible for the 
observed activity. When residue C410 was further assessed for its tolerance to varying amino 
acids, the results indicated that bulkiness at this end of the pocket is important for activation with 
these ligands. Both LCA and chole have reduced molecular volumes compared to the natural 
ligand, 1, 25(OH)2D3. As a result, increased bulkiness at the C410 position may contribute 
additional molecular interactions between the receptor and ligands.  
 Results obtained throughout this work suggest that the end of the hVDR’s LBP consisting 
of two ligand anchoring residues, H305 and H397, and residue C410 tolerates structural 
variations, as numerous variants with mutations at these positions displayed enhanced activity. 
The receptor contains two tyrosines, Y143 and Y147, which were targeted for mutagenesis in one 
of the rationally designed libraries, located at the exact opposite end of the pocket. In an effort to 
gain further insight into the role of these residues at the other end of the LBP, mutagenesis 
assessing the tolerance of tyrosines 143 and 147 was performed. Overall, most changes at these 
positions proved to be detrimental to the function of the receptor supporting the hypothesis that 
this end of the LBP is less tolerant of structural changes, compared to the opposite end consisting 
of residues H305, H397 and C410. 
Overall, a better understanding of the structural and functional relationships between the 
human vitamin D receptor (hVDR) and its ligands was achieved. The effects of residue C410 on 
specificity and activation with the different ligands studied were unforeseen, as this residue does 
not line the receptor’s ligand binding pocket (LBP). However, they serve as an example of the 
significant impact distant residues can have on receptor activation and also emphasize the 
 xvii
important role physical properties of residues, such as volume, can play for specific ends of the 














1.1 The Nuclear Receptor Superfamily 
Nuclear receptors (NRs) are a large family of ligand-activated transcription 
factors. These receptors are found in many organisms, including worms, insects, and 
humans [1]. As of 2001, the genome of Caenorhabditis elegans, a worm, was shown to 
contain 270 NRs, more than any other organism [2-4]. Upon binding of a small molecule, 
NRs function as transcription regulators of essential genes involved in all physiological 
activities, such as development, growth, and homeostasis [1, 5-13]. Due to their 
essential roles in a complex cascade of biological processes, disruption in NR function 
can lead to numerous metabolic diseases, such as diabetes, obesity and cancer [5-8, 
11, 14]. As a result, NRs are good candidates for drug discovery, with 34 of the top 200 
most prescribed drugs targeting a NR in the year 2003 [13].  
Historically, the foundation of the NR superfamily was initiated by the cloning and 
sequencing of the human glucocorticoid receptor (GR) in 1985 and the human estrogen 
receptor  (ER) in 1986 [15-17]. The similarity in sequence between these two 
receptors was indicative of a potential receptor protein family. To date, there are 48 
members in the human NR superfamily [5-8, 11-14, 18-20]. Based on their ligands and 
functions, these receptors are divided into three classes; the endocrine, the adopted 
orphan and the true orphan NRs [5, 19, 21].  Endocrine receptors bind hormones and 
vitamins with high affinity [5, 8, 21]. This class includes steroid as well as non-steroidal 
receptors, such as the progesterone receptor (PR) and the retinoic acid receptor (RAR), 
respectively. The adopted orphan receptors include receptors that were identified 
without the discovery of their natural ligand, such as the pregnane X receptor (PXR). 
These receptors were ‘adopted’, as their natural ligands, ranging from lipids to 
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xenobiotics, were discovered [5, 8, 21]. The third class of receptors, the true orphan 
receptors, is composed of receptors for which ligands have yet to be identified, including 
the short heterodimer partner receptor (SHP) and the liver receptor homolog-1 (LRH-1). 
However, the biological processes regulated by many of these receptors have been 
identified [21]. 
 
1.2 Structure of Nuclear Receptors 
Despite their ability to control a wide variety of processes, NRs share highly 
conserved sequences and modular protein structures that consist of several domains 
(Figure 1.1) [1, 5-8, 11, 13, 22]. Most NR structures include an N-terminal region, a DNA 
binding domain, a hinge region, a ligand binding domain, and a C-terminal region. Each 
domain plays an essential role in the function of NRs. The N-terminal region contains a 
ligand-independent activation function domain (AF-1). This highly variable domain 
serves as the binding site for a variety of proteins including other transcription factors, 
and is the main target for post-translational modifications [12, 14, 19]. The highly 
disordered nature of this region has led to limited information about the structure and 
function of this domain.  
The DNA-binding domain (DBD) is the most conserved domain, with members 
within the NR superfamily sharing high sequence homology. This domain (~70 amino 
acids) contains two cysteine-rich zinc finger motifs necessary for binding specific DNA 
sequences called response elements (REs) (Figure 1.2) [12, 14, 19, 21, 23]. Most REs 
are made up of two hexameric half-sites, usually RGGTCA (where R is a purine), 
separated by several nucleotides [12, 21, 24, 25]. Binding specificity for REs among 
different NRs depends on the spacing (usually 3-5 nucleotides) and orientation (direct or 
indirect repeats) of the two half-sites [24, 25]. Direct repeats are made up of DNA 
sequences that are identical to each other (e.g. AGGTCAxxxAGGTCA), while indirect  
 3
 
Figure 1.1: Structural Domains of Nuclear Receptors (Human RXR) 
DNA Binding Domain (Magenta), Hinge (Yellow), Ligand Binding Domain 













Figure 1.2: DNA Binding Domain of Nuclear Receptors (Human RXR) 
DNA Binding Domain (Magenta), DNA Response Element (Cyan), Zinc (II) 
Ions (Gray), PDB: 3DZY 
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repeats are not. Indirect repeats are subdivided into mirror-image and inverted 
(palindromic) repeats. Mirror-image repeats are made up of DNA sequences that are 
reverse to each other (e.g. AGGTCAxxxACTGGA), while inverted repeats are made up 
of DNA sequences that are also reversed but complement each other (e.g. 
AGGTCAxxxTGACCT).  
The DBD is linked to the ligand –binding domain (LBD) via a non-conserved 
hinge region that provides NRs with flexibility for participation in a diverse array of 
interactions. This domain also includes a nuclear localization sequence, which facilitates 
the transport of some NRs from the cytoplasm to the nucleus [1, 5, 10-13, 21].  
The LBD’s overall structure (~250 amino acids) is well-conserved, but varies 
enough to allow selective ligand recognition among different NRs [8, 11, 13]. This 
domain shares  a common three-dimensional structure typically composed of 12 -
helices and a three-stranded β sheet, arranged in three layers that form an antiparallel 
‘-helical sandwich’ (Figure 1.3) [12, 14, 19, 26, 27]. Residues involved in direct 
interactions/contact with the ligand form the ligand binding pocket (LBP). The specificity 
of NR ligand-binding depends on the shape and volume of this LBP, the amino acid 
residues that are in proximity to the ligand and form direct interactions, as well as distant 
residues that may have indirect structural effects [11]. The LBP’s volume can vary 
significantly among different NRs, for example, the androgen receptor (AR) has a LBP 
volume of 420 Å3, while the peroxisome proliferator-activated receptors (PPARs) have 
LBP volumes of ~1300 Å3 [8, 11, 13]. The LBPs of most NRs are generally lined with 
hydrophobic amino acids and a few polar residues from helices 3, 7 and 10 that mediate 
ligand positioning and interactions [14, 26, 28]. Helix 12, an essential helix in the LBD, 




























































































































mobile lid over the LBP [12, 14, 19, 28, 29]. This domain is also involved in interactions 
with transcriptional coregulators, specifically NR corepressors and coactivators, which 
interact with chromatin-modifying enzymes [12, 14, 20, 30-35].  
Crystallization of partial NR structures has furthered the understanding of NR 
three-dimensional structure and mechanisms of action. However, a significant 
advancement in the structural analysis of NRs occurred with the crystallization of the full-
length liganded NR pair, peroxisome proliferator-activated receptor- (PPAR)-retinoid X 
receptor- (RXR), bound to DNA with coactivator peptides [36, 37]. Unlike previous NR 
crystallization efforts which focused on isolated DBDs and LBDs, this first full-length 
crystal structure provided insight into how domain-domain interactions cooperate and 
ultimately influence NR activity [37]. 
 
1.3 Transcriptional Regulation by Nuclear Receptors 
Due to their roles in a complex cascade of biological processes, the 
transcriptional regulation of NRs involves a series of molecular events. Most NRs are 
regulated by small molecules that are hydrophobic and lipid-soluble in nature [5, 11, 12, 
14]. Generally speaking, NR ligands can be divided into two main categories; agonists 
and antagonists. Agonists are molecules that bind and activate a NR, while antagonists 
are molecules that bind but do not activate a NR [11, 14]. However, both types of ligands 
induce changes in the size and shape of NR LBPs, resulting in the recruitment of diverse 
coregulator complexes (over 300 different proteins identified as of 2007) that interact 





Figure 1.4: Nuclear Receptor Heterodimer (Human PPAR- and Human RXR-) 
Full-length PPAR-/Rosliglitazone (Red/Green), Full-length RXR-/9-cis Retinoic  
Acid (Blue/Yellow), DNA Response Element (Cyan), PDB: 3DZY 
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 Part of the functionality of NRs involves the binding of the NR DBD to specific 
DNA REs. NRs can bind REs upstream or downstream their target genes as monomers, 
homodimers, or heterodimers with the heterodimerizing partner, RXR (Figure 1.4)  [8, 
11, 19, 38, 39]. Based on their activation mode, RXR heterodimer partners are divided 
into three groups; permissive, conditional, and non-permissive heterodimers [5, 8, 19, 
39, 40]. Permissive partners are heterodimers that can be activated by an RXR agonist, 
the other NR’s agonist or both partners’ agonists with an overall additive effect (e.g. 
RXR/LXR (liver X receptor)). Conditional partners do not permit activation by RXR alone 
and require the partner’s agonist for full activation with an RXR agonist (e.g. RXR/RAR). 
Non-permissive partners do not permit activation by RXR agonists, whether the partner’s 
agonist is present or not (e.g. RXR/VDR (vitamin D receptor)).  
In the unliganded apo-form, NRs can be located either in the cytoplasm 
interacting with other proteins (e.g. heat shock proteins and chaperones), or in the 
nucleus and sometimes bound by corepressor complexes [5, 8, 11, 28]. Corepressor 
proteins, such as the nuclear receptor corepressor-1 (NCoR1), contain a corepressor 
nuclear receptor box (CoRNR box) region. An LXXXIXXX(I/L) motif within this box, 
where L is leucine, I is isoleucine and X is any amino acid, binds a hydrophobic surface 
commonly formed by helices 3 and 4 of NR LBDs [8, 11, 13, 19, 41]. Corepressors form 
protein complexes containing histone deacetylases (HDACs). HDACs condense 
chromatin structure over target promoter regions by deacetylating lysine residues on the 
histones, leading to tighter interactions between the histones and DNA. This prevents 
the recruitment of the transcription machinery, resulting in gene repression (Figure 1.5a) 
[8, 11, 12, 19, 21].  
Upon agonist binding, the holo-form of NRs undergoes a conformational change, 
such that helix 12  repositions over the LBP burying the ligand and results in an active 
conformation of the NR (Figure 1.6) [5, 6, 8, 11, 13, 14, 21, 28, 30]. This leads to the 
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Figure 1.6: Apo vs. Holo Nuclear Receptor Ligand Binding Domains (Human 
RXR-) Ligand Binding Domain (Cyan), AF-2 Domain (Red), 9-cis Retinoic Acid 
(Yellow), PDBs:1LBD and 1FBY  
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release of corepressor complexes and the recruitment of coactivator complexes [5, 6, 
11, 19, 28, 34, 35]. Coactivator proteins, such as the steroid receptor coactivator-1 
(SRC-1), also contain a box region where interactions with NRs occur. An LXXLL motif  
within this box binds a hydrophobic surface commonly formed by helices 3, 4 and 12 of 
NR LBDs [8, 11, 13, 14, 19, 42]. Coactivators form protein complexes containing histone 
acetyltransferases (HATs). These enzymes modify the chromatin structure over target 
promoter regions by acetylating lysine residues on the histones, weakening the 
interactions between the histones and DNA. This process facilitates the recruitment of 
general transcription machinery including RNA polymerase, resulting in gene activation 
(Figure 1.5b) [11, 12, 21].  
 
1.4 Nuclear Receptors: Drug Discovery and Protein Engineering Targets 
As previously mentioned, due to the significant role NRs play in biological 
processes and their involvement in a variety of serious diseases; NRs are an important 
target for drug discovery. Owing to the LBD’s multiple functionality (e.g. involvement in 
receptor dimerization, ligand recognition, and coregulator interactions) and ability to bind 
a broad range of ‘drug-like’ small molecules, the LBD has been the NR domain 
predominantly focused on during pharmaceutical development efforts [5, 11, 12, 14, 19, 
29]. Two examples of current commonly prescribed NR-targeting drugs include 
rosiglitazone and tamoxifen (Figure 1.7) [5, 8, 11, 13, 14, 19, 21]. Rosiglitazone targets 
PPAR and is used to treat type II diabetes, while tamoxifen targets ER and is used to 
treat breast cancer. The identification of NR-targeting compounds can be performed 
using several approaches, including crystallographic methods, library screens, and 
synthetic chemistry [13, 14, 21, 43].  
Crystallographic methods provide a three-dimensional analysis and visualization 
of the structures of these receptors, identifying important residues involved in receptor-  
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Figure 1.7: Nuclear Receptor-Targeting Drugs  
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ligand interactions and providing insight on the nature of these proteins in vivo. This 
information can then be used for designing or identifying small molecules for binding 
and/or activation. Library screens involve exposing libraries of the target NR to a variety 
of compounds and assessing their activity, using in vivo or in vitro assays (e.g. binding 
assays and transcription assays). Recently, in-silico library screens have become a 
widely used strategy for this approach, involving computational docking of a variety of 
small molecules into the target NR. The docked receptor-ligand complexes are then 
evaluated based on chemical interactions. Besides being time efficient, this strategy is 
also advantageous in that different NR conformations (e.g. apo vs. holo forms, 
repositioning of the AF-2 domain), as well as interactions between NRs and other 
proteins (e.g. coactivator and corepressor proteins) can be explored [21]. Lastly, 
synthetic chemistry, an approach that can be combined with other methods, involves the 
design and synthesis of novel small molecules, or derivatives of previously identified 
compounds using structure-function information. Efforts on identifying new drugs, as well 
as improving current therapeutic drugs strongly continue to push forward. However, the 
overall challenge continues to lie in overcoming undesired pharmacological effects due 
to NR involvement in complex and overlapping pathways [8, 11, 13, 14].  
In addition to being important targets for drug discovery, NRs are also attractive 
candidates for protein engineering. Although most NRs have the same overall structure, 
the diversity of NRs is partly due to the differences in their ligand binding pockets, thus 
their ability to bind a large array of small molecules. This makes NRs attractive 
candidates for protein engineering, such that these receptors can be engineered to bind 
novel small molecule ligands for several applications. One application is the creation of 
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2.1 The hVDR: Structure and Function 
The human vitamin D receptor (hVDR) is a member of the endocrine receptor 
class of the nuclear receptor (NR) superfamily [1-4]. This receptor was cloned from 
human intestine in 1988, with the natural ligand identified as 1, 25-dihydroxyvitamin D3 
(1, 25(OH)2D3) (Figure 2.1) [5, 6]. The hVDR plays a major role in maintaining calcium 
and phosphate homeostasis, as well as regulating bone metabolism [5, 7-14]. 
Furthermore, this receptor is involved in anti-proliferative, pro-apoptotic and 
immunosuppressive activities in human and mouse cells [7, 13, 15-19].  
To date, eleven other VDR orthologs, the equivalent receptor in a different 
organism, have been reported in species such as the mouse, rat, and zebrafish [20]. 
Additionally, most NRs can exist as isotypes (e.g. , β, )  and isoforms (e.g. 1, 2), 
which are products of post-translational modifications [21]. However, the VDR is the only 
one of its kind in these organisms where no known isotypes or isoforms exist to date. 
The hVDR mainly functions in the small intestine, kidney and bone, heterodimerizing 
with the retinoid X receptor (RXR) as a non-permissive partner (not activated by RXR 
agonists) and binding 1, 25(OH)2D3 [9-11, 22-30]. Liganded hVDR then associates with 
coactivators of the p160 class including the steroid receptor coactivator-1 (SRC-1), 
resulting in the transcription of target genes [31-33]. 
The hVDR is comprised of 427 amino acids, containing a very short N-terminal 
domain with no ligand independent activation function domain (AF-1) [22, 26, 34, 35]. 
The receptor’s DNA binding domain (DBD) consists of ~65-amino acids and binds 
response elements (REs) that consist of two directly repeated half-sites of the  
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Figure 2.1: hVDR Ligands  
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consensus sequence RGKTCA (R=Adenine or Guanine, K=Guanine or Thymine) 
separated by three nucleotides (DR-3), in promoter regions of target genes [4, 11, 22, 
26, 36]. Numerous VDR REs have been identified, such as those of osteocalcin and 
osteopontin, two proteins involved in bone remodeling [22, 37-39]. The hVDR ligand 
binding domain (LBD) consists of 303 amino acids and forms the canonical ‘-helical 
sandwich’, with 13 -helices and a three-stranded β-sheet [3, 4, 35, 40, 41].  
The first solved VDR crystal structure was that of the hVDR LBD bound to 1, 
25(OH)2D3 in 2000 [35]. This structure however, lacks a disordered region of 50-amino 
acids (residues 165-215) between helices 1 and 3 that was removed to facilitate 
crystallization [5, 35]. As previously mentioned, the receptor’s LBD forms the canonical 
‘-helical sandwich’ but the ligand binding pocket (LBP) is 697 Å3, significantly larger 
than that of other endocrine receptors (e.g. estrogen receptor (ER) 369 Å3 and 
progesterone receptor (PR) 422 Å3) and the ligand only occupies 56% of this volume 
(Figure 2.2a) [5, 35, 42]. The elongated LBP is lined with 36 amino acid residues (34 
non-alanine residues), which are mostly hydrophobic [35, 43, 44]. 1, 25(OH)2D3’s 
conformation is such that the A-ring of the structure is positioned towards helices 3 and 
5, while the aliphatic chain is positioned towards helices 7 and 10/11 [35].  
Interactions between the receptor and 1, 25 (OH)2D3 involve both hydrophobic 
and electrostatic interactions, with residues Y143, S237, R274, S278, H305 and H397 
forming important hydrogen bonds (Figure 2.3) [5, 35]. In looking at specific interactions 
between the ligand and the receptor, when bound to 1, 25(OH)2D3, the hVDR’s ligand 
dependent activation function domain (AF-2) is found in the active conformation (Figure 
2.2b) [35]. Residues V418 and F422 in helix 12 make Van der Waals contacts with the 
methyl group of the ligand. The position of this helix overall, is stabilized by hydrophobic 




















































































Figure 2.3: Important Hydrogen Bonds between 
the hVDR and 1, 25(OH)2D3 hVDR Residues 


















Unlike other ligands which stabilize helix 12 through direct interactions, the 
hVDR’s ligand induced effect on helix 12 with 1, 25(OH)2D3 takes place through a ‘pi-
cation activation switch’ conserved among several NRs [45, 46]. This switch involves an 
electrostatic interaction between H397 in helix 11 and F422 in helix 12. The oxygen 
group on the aliphatic chain of 1, 25 (OH)2D3 directly interacts with H397 but not F422. 
However, the interaction between these two residues helps stabilize helix 12 in the 
active conformation [35, 45]. This interaction optimizes the distance between residues 
K264 in helix 4 and E420 in helix 12, which form a ‘charge-clamp’ involved in coactivator 
binding surfaces (Figure 2.4) [4, 47-49]. 
The hVDR also binds bile acids such as lithocholic acid (LCA), which is produced 
in the liver, excreted in the bile and partially reabsorbed by the intestines (Figure 2.1). 
This acid is a carcinogenic compound implicated with the progression of colon cancer 
[28, 50-52]. Binding to bile acids has been shown to induce activity of enzymes involved 
in cellular clearance of xenobiotic and endobiotic compounds (e.g. cytochrome P450 
genes), which led to the hypothesis of the hVDR’s involvement in preventing 
carcinogenic effects [5, 28, 50, 53-55].  
No crystal structure of the hVDR bound to LCA is currently available, however 
given the structural differences between LCA and 1, 25(OH)2D3 different receptor-
ligand interactions are involved. For example, LCA lacks the 1-hydroxyl group on the A-
ring and therefore cannot form the hydrogen bond that 1, 25(OH)2D3 forms with S237 
[28, 35, 50, 52]. Several hypotheses indicate that LCA binding results in a compromised 
positioning of helix 10 which is involved in dimerization interactions between the hVDR 
and RXR, and helices 3 and 12 which are involved in coactivator interactions [28]. These 
differences must account for a certain degree of the lower sensitivity of LCA (EC50= 12.1 
µM) for the hVDR, compared to that of 1, 25(OH)2D3 (EC50= 2-5 nM) 
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Figure 2.4: The hVDR ‘Pi-Cation Activation Switch’ and ‘Charge Clamp’ 
hVDR Residues (Purple), 1, 25-dihydroxyvitamin D3 (Cyan), PDB:1DB1 
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 [28, 35, 50, 52, 55-60]. Despite differences in receptor-ligand interactions, LCA and 1, 
25(OH)2D3 may share a similar conformation in the hVDR LBP, as the 3-hydroxyl group 
on the A-ring of both molecules forms a hydrogen bond with residues Y143 and S278 
[28]. Additionally, the functional group on the aliphatic chain of both molecules forms a 
hydrogen bond with residue H305 [28].  
 
2.2 The hVDR: A Drug Discovery Target 
Mutations in the hVDR lead to insufficient ligand activation, thus resulting in an 
imbalance of physiological levels of 1, 25(OH)2D3 and Rickets [5, 35, 61-68]. Rickets is 
a disease associated with muscle weakness, growth retardation and bone deformity [5, 
35, 61-68]. Due to the hVDR’s negative-feedback mechanism, certain types of rickets 
and other related conditions including osteoporosis and psoriasis, can be clinically 
treated with 1, 25(OH)2D3 [5, 13, 59, 69, 70]. However, undesirable calcemic effects 
that result in hypercalcemia, increased bone resorption, and soft tissue calcification limit 
the use of pharmacological doses. This has lead to the development of 1, 25(OH)2D3 
analogs with reduced side effects [5, 7, 13, 35, 52, 71].  
To create analogs of 1, 25(OH)2D3 without severe side effects, the aliphatic 
chain of 1, 25(OH)2D3 has been the main target of chemical modifications, as the A-D 
rings have not been successfully changed without loss of ligand activation [35]. Two 
known examples are calcipotriol and seocalcitol (Figure 2.1). Calcipotriol is used for 
topical treatment of psoriasis, while seocalcitol underwent clinical studies for cancer 
treatment [72-77]. Non-secosteroidal mimics such as derivatives of LG190090, have 
also been developed for potential treatment of cancer, leukemia and psoriasis (Figure 
2.1) [60]. More than 3,000 1, 25(OH)2D3 analogs have been developed, with few 
advancing past clinical trials [42, 44, 49, 57, 59, 69, 78-81].  
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Although agonists have been the focus of hVDR targeted drugs, a few 
antagonists have also been developed. As previously mentioned, antagonists are small 
compounds that bind but do not activate a receptor due to improper conformational 
changes and NR-corepressor interactions, resulting in transcriptional repression of target 
genes [82]. hVDR antagonists are of interest because of their ability to treat conditions 
such as Paget’s disease, which is associated with excessive breakdown and formation 
of bone tissue, and as a result bone pain, deformities and fractures [83]. hVDR 
antagonists have been reported to reduce excessive bone resorption, as well as the 
formation of cells involved in bone resorption [84, 85]. Two examples of hVDR 
antagonists are ZK159222 and TEI-9647, and compared to 1, 25(OH)2D3 (agonist), 
these compounds have bulky ring structures on their side chains, inhibiting optimal 
interaction between the positioning of helix 12 and the rest of the receptor (Figure 2.1) 
[42, 86-88]. ZK159222 is a potent antagonist, binding hVDR with an affinity comparable 
to that of 1, 25(OH)2D3, while TEI-9647 is a weaker antagonist [42, 88].   
 
2.3 The hVDR: A Protein Engineering Target 
As previously mentioned NRs play essential roles in biological functions and are 
involved in a variety of diseases. These traits make NRs great targets for drug discovery, 
specifically discovery of ‘drug-like’ small molecules that bind the receptor’s LBD. The 
specificity of NR ligand-binding depends on the shape and volume of the LBP within the 
LBD, the amino acid residues that are in proximity to the ligand and form direct 
interactions, as well as distant residues that may have indirect structural effects [89]. In 
addition to being important targets for drug discovery, NRs are also attractive targets for 
protein engineering. Although most NRs have the same overall structure, they can 
significantly differ in LBP volumes and can therefore bind a wide array of small 
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molecules (Figure 2.5) [7, 58]. For example, RXR binds retinoids containing a cyclic end 
group, a polyene side chain and a polar end group. ER binds estrogens which are 
steroids consisting of four cyclic rings fused to each other. The pregnane X receptor 
(PXR), which binds the large macrolide rifampicin, is known as a promiscuous receptor 
that binds a variety of ligands. This diversity of ligands for NRs, makes NRs attractive 
candidates for protein engineering, such that these receptors can be engineered to bind 
novel small molecules for several applications. One application is the creation of 
molecular switches, tools that can be used for controlling gene expression [90, 91].  
The focus of this work has been to investigate the human vitamin D receptor 
(hVDR), specifically structural and functional relationships between the receptor and its 
ligands. Throughout this process, the role and mutational tolerance of specific residues 
within the ligand binding domain of the hVDR were investigated. The hVDR variants 
engineered by methods of rational and random mutagenesis were tested using chemical 
complementation [90, 92].  
 
2.4 Chemical Complementation: A Genetic Selection System in Yeast 
A genetic selection system like chemical complementation, where the interaction 
between a protein and a small molecule is evaluated, serves as a powerful tool for 
protein engineering and drug discovery applications [21, 90-93]. Chemical 
complementation (CC) is a genetic selection system in which the survival of yeast, 
Saccharomyces cerevisiae, is linked to the binding and activation of a NR by an agonist, 
as the activation of the NR results in the transcription of an essential gene [90-92]. Yeast 
is a suitable organism for studying NR-ligand interactions, as they naturally do not have 
NRs, limiting NR interference in the assay. Additionally, their transcription machinery is 
similar to mammalian transcriptional machinery, allowing proper expression and 



















Figure 2.5: Ligands of Various Nuclear Receptors 
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CC was developed using the PJ69-4A yeast strain, a yeast two-hybrid strain with 
the expression of genetic selection genes, HIS3 and ADE2, and a screening gene, lacZ, 
under the control of Gal4 REs [94]. Gal4 is a ligand-independent transcription factor 
naturally found in yeast [95]. As a modular protein, Gal4 contains a DBD that binds Gal4 
REs, and an activation domain (AD) that interacts with transcriptional machinery.  
In CC, the Gal4 DBD is fused to a NR LBD, the Gal4 AD is fused to a human 
coactivator, and a small molecule ligand is introduced (Figure 2.6) [90, 92]. In this 
system, the Gal4 DBD:NR LBD fusion protein binds Gal4 REs and an agonist binds the 
NR LBD inducing a conformational change that leads to the recruitment of the 
corresponding Gal4 AD:coactivator fusion protein and the transcriptional machinery. 
Hence there is expression of a selective gene; the HIS3 or ADE2 gene, essential genes 
in the corresponding histidine or adenine biosynthetic pathway. Transcription of HIS3 or 
ADE2 allows the PJ69-4A yeast strain to produce histidine or adenine and survive on 
media lacking that nutrient. Therefore, only ligand activated NRs will result in the survival 
of yeast. Overall, CC provides simple and rapid detection of NR activation, making this 
selection system useful for semi high-throughput screening [21].  
 
2.5 Characterization of the hVDR in Chemical Complementation 
In order to use the hVDR and test the functionality of this receptor in chemical 
complementation, the hVDR gene was isolated and amplified from skin cDNA using 
polymerase chain reaction (PCR) and cloned into a yeast expression plasmid. The 
resulting construct, pGBDhVDR, contained the Gal4 DBD fused to the full length hVDR 
and a tryptophan marker. This construct along with another yeast expression plasmid, 
pGAD10BASRC-1, containing the Gal4 AD fused to the SRC-1 coactivator and a leucine 
marker were co-transformed into the PJ69-4A yeast strain (Figure 2.7). As a positive 
control, the yeast expression plasmid pGBT9Gal4, containing the holo Gal4 gene and a  
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Figure 2.6: Chemical Complementation  
A genetic selection system in which the survival of yeast is linked to the 
binding and activation of a nuclear receptor by an agonist. 
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Figure 2.7: Cloning the hVDR from cDNA and Co-transformation into the 
PJ69-4A Yeast Strain
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tryptophan marker was also co-transformed with pGAD10BASRC-1 into the PJ69-4A 
strain. The resulting transformants were then tested in chemical complementation using 
a liquid based assay. 
Liquid quantitation assays of chemical complementation are performed in 96-well 
plates, where yeast cells containing the fusion proteins (Gal4 DBD:NR LBD and Gal4 
AD:coactivator) of interest are added to wells with and without ligand (Figure 2.8). As 
previously mentioned, the PJ69-4A yeast strain uses the HIS3 or ADE2 gene, essential 
genes in the corresponding histidine or adenine biosynthetic pathway. As a result, all 
wells contain selective media lacking an essential nutrient, either synthetic complete 
media lacking histidine, leucine and tryptophan (SC-HLW) or synthetic complete media 
lacking adenine, leucine and tryptophan (SC-ALW).  Plates are then incubated at 30 ºC 
with shaking, and optical density readings at a wavelength of 630 nm (OD630) are taken 
at 0, 24 and 48 hours. Wells with yeast growth are an indication of the small molecule 
ligand binding and activating the NR, turning on the transcription of the selective gene 
and consequently yeast survival (ligand activated growth).   
The hVDR was first tested in adenine selective media (SC-ALW) with varying 
concentrations of ligand. Due to the expense of the hVDR’s natural ligand, 1, 
25(OH)2D3, LCA was used to collect this set of data. No ligand activated growth was 
observed for the hVDR in adenine selective media with LCA, as shown in Figure 2.9 
where no curve is observed. Gal4 is a ligand independent transcription factor and is 
used as a positive control. As expected, Gal4 grew with and without ligand at an optical 
density of ~0.5 (Figure 2.9). 
The HIS3 gene which encodes imidazoleglycerol-phosphate dehydratase, an 
essential enzyme in the histidine biosynthetic pathway, is known as a ‘leaky gene’ with 
some basal activity [96]. As a result, 3-amino-1, 2, 4-triazole (3-AT), an inhibitor of 
imidazoleglycerol-phosphate dehydratase, is used to reduce basal growth (Figure 2.8).  
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Figure 2.9: The wthVDR in Chemical Complementation   
Adenine selective media with LCA 
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To determine the concentration of 3-AT necessary to reduce the HIS3 basal expression 
with the hVDR, the receptor was tested in liquid quantitation assays of chemical 
complementation in histidine selective media (SC-HLW) with varying concentrations of 
3-AT, with and without ligand. Again, due to the expense of 1, 25(OH)2D3, LCA (100 
µM) was used to collect this set of data. Based on the 3-AT dose response curve without 
ligand, we determined that an optical density of ~0.145 is the basal growth associated 
with the hVDR in histidine selective media. This growth was reduced to ~0.093 upon the 
addition of 0.1 mM 3-AT. Higher concentrations of 3-AT did not reduce the basal growth 
further (Figure 2.10a). Ligand activated growth above basal was observed for the hVDR 
in histidine selective media with 0.1 mM 3-AT and 100 µM LCA, with a two-fold activation 
(Figure 2.10b). As a result, 0.1 mM 3-AT should be used when testing the hVDR in 
histidine selective media, as this concentration of 3-AT reduced the basal expression 
associated with the receptor without eliminating ligand activated growth. 
 The hVDR was then tested in liquid quantitation assays of chemical 
complementation in histidine selective media with 0.1 mM 3-AT and varying 
concentrations of 1, 25(OH)2D3, lithocholic acid, and various analogs of the two ligands 
(Figure 2.11). Ligand activated growth was observed with 1, 25(OH)2D3, calcipotriol, 
calcifediol, lithocholic acid and lithocholic acid acetate with four-, five-, five-, three- and 
four-fold activations, respectively. Besides good fold activations, most ligands resulted in 
an optical density of ~0.4 at the highest ligand concentration, which is comparable to the 
growth previously observed with Gal4 (positive control) (Figure 2.12). The EC50 values 
(half maximal effective concentrations), which refer to the ligand concentration that 
induces a response half-way between the baseline and maximum response, in CC with 
each ligand were in agreement with previously reported literature EC50 values in 




Figure 2.10: The wthVDR in Chemical Complementation  




Figure 2.11: 1, 25(OH)2D3, Lithocholic Acid and their Analogs 
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Figure 2.12: The wthVDR in Chemical Complementation  
Histidine selective media with various ligands
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observed with cholecalciferol, a precursor in the 1, 25(OH)2D3 biosynthetic pathway 
(Figure 2.12). Based on these results, chemical complementation has proven to be a 
suitable system for studying the human vitamin D receptor.  
The hVDR was also tested in liquid quantitation assays of chemical 
complementation in adenine selective media with varying concentrations of its natural 
ligand, 1, 25(OH)2D3.  A 10-fold activated growth and an EC50 value of 5.14 nM was 
observed (Figure 2.13). Based on these results and those previously obtained in 
adenine selective media with LCA (no ligand activated growth, Figure 2.9), we conclude 
that the ADE2 selection system is too stringent for testing hVDR ligands associated with 
low sensitivity (weak receptor-ligand pairs e.g. hVDR-LCA) but not for ligands associated 
with high sensitivity (strong receptor-ligand pairs e.g. hVDR-1, 25(OH)2D3). Overall, the 
hVDR can be used in chemical complementation, providing results similar to those 
obtained in mammalian cell culture. 
 
2.6 Summary 
In addition to being important targets for drug discovery, nuclear receptors (NRs) 
are also attractive candidates for protein engineering. In order to engineer and use the 
human vitamin D receptor (hVDR) in chemical complementation, a genetic selection 
system in which the survival of yeast is linked to the activation of a NR by an agonist, the 
hVDR gene was isolated from cDNA and the receptor’s functionality was tested in liquid 
quantitation assays of chemical complementation. Chemical complementation proved to 
be a suitable system for studying this receptor, providing results similar to those 
previously reported for mammalian cell culture assays. As a result, the structural and 
functional relationships between the hVDR and its ligands can be investigated using 


























Figure 2.13: The wthVDR in Chemical Complementation 
Adenine selective media with 1α, 25(OH)2D3 
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2.7 Materials and Methods 
Ligands 
1α,25-dihydroxyvitamin D3 and calcifediol were purchased from BIOMOL 
(Plymouth Meeting, PA). Calcipotriol was purchased from Waterstone Technology 
(Carmel, IN). Lithocholic acid and lithocholic acid acetate were purchased from MP 
Biomedicals, LLC (Solon, OH). Cholecalciferol was purchased from Sigma-Aldrich (St. 
Louis, MO). 10 mM stocks of all ligands, except 1α,25-dihydroxyvitamin D3, for which a 
13.3 µM stock was made, were made with 80 % ethanol: 20 % dimethyl sulfoxide 
(DMSO) and stored at 4 °C.  
 
hVDR Gene Isolation and Construction of a Yeast Expression Plasmid 
The human vitamin D receptor gene was isolated and amplified from human skin 
cDNA (BioChain, Hayward, CA) via PCR (55 ºC as the annealing temperature) using 
125 ng of the following primers: 5’-gcc gga att cat gga ggc aat ggc ggc-3’ and 5’-gga cta 
gtt cag gag atc tca ttg cca aac ac-3’ (Operon, Huntsville, AL). The underlined sequences 
denote EcoRI and SpeI restriction sites, respectively. The hVDR gene and yeast 
expression plasmid pGBT9, which contains the Gal4 DBD, were digested with EcoRI 
and SpeI, ligated, and transformed into Z-competent™ XL-1 Blue Escherichia coli 
(E.coli) cells (Zymo, Orange, CA).  The resulting plasmid, pGBDhVDR, contained the 
Gal4 DBD fused to the full-length hVDR, and a tryptophan marker. All DNA was purified 
using the QIAprep® Spin Miniprep Kit (Qiagen, Valencia, CA). The pGBDhVDR plasmid 
was sequenced for confirmation (Operon, Huntsville, AL).  
 
Yeast Transformation Using the PJ69-4A Strain 
Using the 1x TRAFCO yeast transformation protocol, ~500 ng of the yeast 
expression plasmids, pGBDhVDR (containing the Gal4 DBD fused to the full-length 
 45
hVDR and a tryptophan marker) and pGAD10BASRC-1 (containing the Gal4 AD fused 
to SRC-1 and a leucine marker), were co-transformed into the yeast strain PJ69-4A [97]. 
Transformants were plated onto non-selective synthetic complete agar plates lacking 
leucine and tryptophan (SC-LW) to select for both fusion plasmids. Plates were 
incubated at 30 ºC for 3-4 days.  
 
Liquid Quantitation Assays of Chemical Complementation in Yeast 
Transformants obtained from the yeast transformation were grown overnight in non-
selective SC-LW media, at 30 ºC with shaking at 300 rpm. A 4:1 ratio of selective media 
(SC-ALW or SC-HLW) with and without ligand at varying concentrations: cells (yeast 
resuspended in water) were aliquoted into 96-well plates. Plates were then incubated at 
30 ºC with shaking at 170 rpm for 48 hours, with optical density readings at a 
wavelength of 630 nm (OD630) taken at 0, 24 and 48 hours. All data points represent 
the mean of at least duplicate experiments and the bars indicate standard deviation. The 
lowest ligand concentration data points for all plots contain no ligand. EC50 values were 
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PROTEIN ENGINEERING WITH CHEMICAL COMPLEMENTATION: ENGINEERING 
THE HUMAN VITAMIN D RECEPTOR TO BIND AND ACTIVATE IN RESPONSE TO A 




3.1 Engineering the hVDR 
The human vitamin D receptor’s (hVDR) significant role in biological processes 
and involvement in diseases makes this receptor an important target for drug discovery, 
and an attractive candidate for protein engineering. Based on this fact and the severe 
effects of mutations on the hVDR’s function (discussed in Chapter 2), investigating the 
structure- function relationships between the hVDR and its ligands is of interest. The 
information gained can be applied towards further understanding of the functionality of 
the receptor, its ability to bind various ligands, and for further development of new small 
molecules as potential therapeutic drugs.  
Previous structural and mutational analyses of the hVDR have focused on 
alanine scanning mutagenesis and site-directed mutagenesis of the residues lining the 
receptor’s ligand binding pocket (LBP). These studies have provided a fundamental 
understanding of the key interactions between the hVDR and various ligands; however 
work on the mutational tolerance of LBP residues or the indirect effects of residues 
outside the LBP have been limited. 
 To investigate the structural and functional parameters of the hVDR further, as 
well as gain insight into the role and tolerance of specific residues, a mutational 
assessment of residues in the hVDR ligand binding domain (LBD) was performed. To 
develop a comprehensive mutational analysis, libraries of hVDR variants were 
engineered using two approaches. In the first approach, structural analyses allowed the 
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rational design of two libraries using randomized codons at chosen positions. The 
second approach involved random mutagenesis, using error-prone PCR (epPCR) to 
create libraries of variants. All of the variants obtained were tested with small molecule 
ligands of interest using chemical complementation. As discussed in Chapter 2, 
chemical complementation proved to be a suitable system for studying the hVDR, 
providing results similar to those obtained in mammalian cell culture assays. 
While evaluating and developing a deeper understanding of the hVDR, part of 
the goal was to engineer this receptor to bind and activate in response to a novel small 
molecule and not its natural ligand, 1, 25(OH)2D3. The diversity of ligand binding 
among different nuclear receptors (NRs) suggests the possibility of engineering these 
receptors to bind novel small molecules for several applications [1, 2]. Specific interest 
laid in determining whether selective pressure would allow for the directed evolution of a 
variant that would be activated by cholecalciferol (chole) or a β-lactam antibiotic (Figure 
3.1a). Chole, a precursor in the 1, 25(OH)2D3 biosynthetic pathway lacks two of the 
three hydroxyl groups present in 1, 25(OH)2D3 and does not activate the hVDR, 
confirming the importance of precise molecular interactions required for ligand activation. 
β-lactam antibiotics, on the other hand, are a large component of the 
pharmaceutical industry worldwide. However, some of the major challenges faced in the 
synthesis and manufacturing of these drugs are high costs and excessive waste 
production, as well as patient drug resistance [3]. As a result, alternatives to current 
synthetic approaches are needed. One such approach would be to develop microbial 
‘factories’ that produce β-lactam antibiotics, resulting in reduced costs and labor, yet 
higher yields. Engineering NRs to bind these antibiotics in chemical complementation 
provides a selection method for detection of the small molecules being produced in 
yeast (Figure 3.1b). The selective pressure placed on the yeast ensures that the  
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Figure 3.1: Engineering the hVDR to Bind and Activate in Response to a    
Novel Small Molecule Ligand (a) Structures of molecules of interest            
(b) Engineering nuclear receptors for the development of microbial systems 
that produce antibiotics  
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biosynthetic genes required are maintained by the organism, allowing the production of 
the β-lactam antibiotics in this microbial system. If selective pressure is not present, 
yeast would eventually lose the need to produce these antibiotics over several 
generations. 
The goal of this project was to use rational and random mutagenic approaches, 
along with chemical complementation to engineer the hVDR to activate in response to a 
β-lactam antibiotic for future use in antibiotic production, and chole to explore how a 
molecule extremely similar to the natural ligand can contribute to a completely different 
activation profile with the wild-type receptor. The latter is a result likely due to differing 
receptor-ligand structure-function relationships between the receptor and these two 
molecules (Figure 3.1). 
 
3.2 Rational Mutagenic Approach: hVDR Libraries 1 & 2 
3.2.1 Rational Mutagenic Approach: Design for hVDR Libraries 1 & 2 
Rational design of proteins is a process in which knowledge of the structure and 
function of a protein is used to create desired changes or mutations. A rational 
mutagenic approach consisting of multiple strategies was utilized to engineer hVDR 
libraries. First, the hVDR’s crystal structure with 1, 25(OH)2D3 (PDB:1DB1) was 
analyzed for residues within five angstroms of the ligand [4]. Using the molecular 
graphics software program, Visual Molecular Dynamics (VMD), as a visualization and 
analysis tool of the three-dimensional crystal structure, key molecular  interactions in the 
hVDR’s LBP were determined [5]. Previous literature on mutational analyses assessing 
the structure-function relationship between the receptor and the ligand was also used as 
a determinant for the specific residues that were to be mutated, minimizing library size in 
our rational design to the coverage capabilities of yeast [6-11]. Yeast transformations 
generate a maximum of ~106 transformants/µg plasmid DNA [12]. Ideally, in order to 
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obtain complete library coverage, library size in yeast should be limited to ~105-106 
variants or smaller. Overall, 14 residues were chosen and mutations at each position 
were designed based on amino acid properties (e.g. polarity, shape and volume). 
Mutations were also chosen based on sequencing alignments of the hVDR with other 
NRs, including the pregnane X receptor (PXR), retinoid X receptor (RXR) and estrogen 
receptor (ER), focusing on evolutionarily conserved and non-conserved residues [13]. 
Two rationally designed hVDR libraries (1 & 2) were created in quest of exploring 
how chemical and physical changes within the LBP affect receptor-ligand interactions, 
thus receptor function. For hVDR library 1, several residues that interact directly with 1, 
25(OH)2D3  and/or predicted to have an effect on stabilizing the active conformation of 
the receptor were chosen for mutagenesis [8-10]. For example, residues S237 (helix 3), 
R274 (helix 4/5) and H397 (helix 11) form important hydrogen bonds with the ligand, 
while residues I238 (helix 3) and F422 (helix 12) are located in helices that interact with 
coactivator proteins, thus stabilizing the active conformation of the receptor [4, 14]. 
Seven residues were targeted for mutagenesis in library 1: S237, I238, I271, R274, 
H397, Y401 and F422 (Figure 3.2 and Table 3.1).  
For hVDR library 2, a different subset of residues predicted to have an effect on 
stabilizing the active conformation of the receptor and/or ligand- mediated 
conformational changes of the receptor were chosen for mutagenesis [8-10]. For 
example, residues Y147 (loop 1-3) and L233 (helix 3) not only interact with the ligand, 
but also form interactions with other residues that contribute to structural changes of the 
receptor upon ligand binding, leading to the active conformation. Seven residues were 
targeted for mutagenesis in library 2: Y143, Y147, F150, L227, L233, Y295 and V418  
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Figure 3.2: Rational Mutagenic Approach: Design for hVDR Library 1 
Mutated hVDR Residues (Cyan), 1, 25(OH)2D3 (Yellow), PDB:1DB1     
Subscripts indicate amino acids that appear with more than one codon at the 








Figure 3.3: Rational Mutagenic Approach: Design for hVDR Library 2 
Mutated hVDR Residues (Cyan), 1, 25(OH)2D3 (Yellow), PDB:1DB1 
Subscripts indicate amino acids that appear with more than one codon at the 












(Figure 3.3 and Table 3.2). Overall, these residues were predicted to be important for the 
function of the hVDR and hypothesized to exhibit low tolerance for mutation. 
As previously mentioned, mutations at each position targeted for mutagenesis 
were designed based on amino acid properties and sequencing alignments of the hVDR 
with other NRs. Overall, hydrophobic residues were mutated to residues with similar 
chemical properties, maintaining the hydrophobicity of the LBP. For example, residues 
I271 and V418 were mutated to leucine, isoleucine, valine, phenylalanine and 
methionine. Residue Y401 is a conserved leucine in PXR, RXR and ER; thus this 
residue was saturated with all amino acids to explore whether amino acids besides 
tyrosine or leucine would be tolerated in the hVDR. Residue Y295 on the other hand is 
conserved among PXR and the hVDR, but is a valine in RXR and a leucine in ER. As 
a result, this position was mutated to amino acids of similar properties such as serine, 
phenylalanine and isoleucine, as well as residues of significantly different properties 
such aspartic acid and arginine. The theoretical library size at the amino acid level for 
library 1 was 5 x 106 variants, and 5 x 105 variants for library 2 (Figures 3.2 and 3.3). 
 
      3.2.2 Rational Mutagenic Approach: Library Construction and Selection of     
  hVDR Libraries 1 & 2 in Chemical Complementation 
The variants of each hVDR library were constructed using oligonucleotides with 
randomized degenerate codons at the chosen mutation sites (Tables 3.3 and 3.4). 
These synthetic oligonucleotides (oligos) were designed to contain overlapping 
complementary ends with the former and latter oligonucleotide in sequence, forming a 
full insert cassette via a combination of hybridization and PCR [15]. The 5’ and 3’ ends of 
the full insert cassette also contained complementary sequences (~100 bp) to the 
background plasmid (pGBDhVDRBackground), a vector used for decreasing the  
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expression of the wild-type hVDR (wthVDR) in the libraries. This yeast expression 
plasmid contains the Gal4 DNA binding domain (DBD) fused to a portion of the hVDR 
followed by a random sequence of DNA that introduces multiple STOP codons. This 
results in a non-functional protein when translated and therefore decreases the presence 
of the wthVDR in the libraries. Once transformed into the PJ69-4A yeast strain, through 
homologous recombination, the insert cassettes and digested background plasmid 
recombine generating yeast expression plasmids that contain the Gal4 DBD fused to the 
hVDR variants, and a tryptophan marker (Figure 3.4). 
For each hVDR library, the full insert cassette, the digested background plasmid 
(pGBDhVDRBackground), and the yeast expression plasmid pGAD10BAACTR 
(containing a leucine marker and the Gal4 activation domain (GAD) fused to the 
activator for thyroid and retinoid receptors (ACTR)), were transformed into the PJ69-4A 
yeast strain. Transformants were plated onto non-selective synthetic complete agar 
plates lacking leucine and tryptophan (SC-LW) to select for both plasmids and to 
determine whether homologous recombination occurred. As discussed in Chapter 2, the 
PJ69-4A yeast strain contains the HIS3 and ADE2 genes, essential genes in the 
corresponding histidine or adenine biosynthetic pathway, under the control of Gal4 
response elements. As a result, transformants were also plated onto adenine or histidine 
selective agar plates (SC-ALW or SC-HLW+0.1mM 3AT) containing β-lactam antibiotics 
and several additional small molecule ligands. The first ligand set contained amoxicillin, 
cloxacillin, and penicillin G, as well as, 17-β-estradiol (ligand for ER) and -1-oxo-
pyrenebutyric acid (Figure 3.1a). The second ligand set contained ampicillin and 
oxacillin, as well as, hexestrol (ligand for ER), 9-cis retinoic acid (ligand for RXR), and 










Figure 3.4: Using Hybridization and PCR to Create Full Insert Cassettes, 
Construction of the Background Plasmid and Transformation into PJ69-4A 
for hVDR Libraries 1 & 2 
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Rational Mutagenic Approach: Results for hVDR Libraries 1 & 2 
The non-selective (SC-LW) plates were used to determine the experimental 
library size at the amino acid level and transformation efficiency of each hVDR library. 
The transformation produced a library size of 3.7 x 103 variants with a 6.15 x 104 cfu/µg 
plasmid DNA transformation efficiency for library 1, and 5.3 x 103 variants and 1.08 x 105 
cfu/µg plasmid DNA for library 2, respectively. Potentially ligand activated variants 
selected from the various ligand plates (~2-3 % of each experimental library) were re-
tested on solid media plates for constitutive activity. Constitutive activity is growth 
observed in selective media without the presence of an exogenous small molecule 
ligand. For each hVDR library, selective colonies were streaked onto non-selective 
plates (SC-LW), as well as adenine and histidine selective plates (SC-ALW and SC-
HLW+0.1 mM 3-AT) with and without ligand. A subset of variants was also tested in 
liquid quantitation assays of chemical complementation (data not shown). Streaking 
indicated that most of the variants were constitutively active, displaying growth on 
selective plates lacking ligand, as shown in Figure 3.5.  
Twelve variants from each hVDR library were submitted for sequencing, and over 
95 % of the sequenced variants contained frame-shift mutations due to random 
insertions and deletions of bases. After careful evaluation of all the sequences, the 
majority of the sequenced variants displayed insertions and deletions in the overlap 
regions between oligos, indicating a failure in the hybridization and PCR protocol. 
Several strategies were pursued in an attempt to solve this problem. 
 
      3.2.3 Rational Mutagenic Approach: Troubleshooting hVDR Libraries 1 & 2    
  Using Klenow Polymerase 
 The first strategy to reduce the number of frame-shifts observed in the rationally 




Figure 3.5: Rational Mutagenic Approach: Streaking for hVDR Library 1 
& 2 Variants Most of the variants were constitutively active, displaying growth 
on selective plates lacking ligand. Please disregard circles. 
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library. Like Pfu, Klenow is a high fidelity polymerase facilitating DNA synthesis with a 
reduced error frequency, compared to other polymerases [16, 17]. A combination of 
Klenow and Pfu was used, where the hybridization step was followed by an extension 
step, with Klenow completing the overhang pieces of DNA from the 5’ to 3’ direction [17]. 
Klenow instead of Pfu in essence should reduce the number of insertions and deletions. 
The number of cassettes was exponentially amplified via PCR, with Pfu and the 
corresponding forward and reverse primers. Several conditions with Klenow were used 
to construct the full insert cassette of hVDR libraries 1 & 2: (1) varying the concentration 
of each oligo and primers (2) varying the number of oligos combined at a time (3) 
varying PCR conditions for the amplification step (e.g. annealing temperature and 
number of cycles) and (4) using longer amplification primers. Small cassettes were 
successfully created using Klenow polymerase, however the full insert cassette (1096 
bp) of each hVDR library was not obtained. Most of the conditions resulted in smaller 
cassettes or smears when analyzed on agarose gels, as shown in Figure 3.6.  
 
      3.2.4 Rational Mutagenic Approach: Troubleshooting hVDR Libraries 1 & 2  
  Using Commercial Pfu Polymerase 
Another strategy taken to reduce the number of frame-shifts observed in the 
rationally designed libraries was the use of a commercial Pfu polymerase (Stratagene, 
Santa Clara, CA), instead of the Pfu polymerase expressed and purified in-house. 
Several conditions (as described above for Klenow polymerase) using a combination of 
Klenow and the commercial Pfu were used to create the full insert cassette of each 
library, but yielded no success. However, cassettes 1 (oligos 1-8, 607 bp) (Figure 3.7a, 
lanes 2 and 4) and cassettes 2 (oligos 9-14, 506 bp) (Figure 3.7a, lanes 3 and 5) were 
successfully made and combined using the commercial Pfu alone to form the full insert 




Figure 3.6: Rational Mutagenic Approach hVDR Libraries 1 & 2: Examples 
of Cassette Products Obtained Using Klenow Polymerase  
(a) Lane 1: λ DNA-HindIII marker, Lane 2: cassette 1 (oligos 1-8) + oligos 9, 
10, 11, 12, 13 and 14 for hVDR library 1, Lane 3: same as lane 2, except for 
hVDR library 2, Lane 4: cassette 1(oligos 1+2) + cassette 2 (oligos 3+4) + 
cassette 3 (oligos 5+6) + cassette 4 (oligos 7+8) + oligos 9, 10, 11, 12, 13 and 
14 for hVDR Library 1, Lane 5: same as lane 4, except for hVDR Library 2  
(b) Lane 1: 100 bp marker, Lane 2: cassette 1(oligos 1-8) + cassette 2 (oligos 
9+10) + cassette 3 (oligos 11+12) + oligos 13 and 14, Lane 3: same as lane 2, 
except for hVDR library 2, Lane 4: cassette 1 (oligos 1+2) + cassette 2 (oligos 
3+4) + cassette 3 (oligos 5+6) + cassette 4 (oligos 7+8) + cassette 5 (9+10) + 
cassette 6 (oligos 11+12) + oligos 13 and 14, Lane 5: same as lane 4, except 
for hVDR library 2.  
The full insert cassette (1096 bp) of each library was not obtained, but was 









































































































































































































































































































































            For each hVDR library, the full insert cassette (3.5 µg), the digested background 
plasmid (pGBDhVDRBackground) (1 µg), and the coactivator plasmid 
(pGAD10BAACTR) (1 µg) were transformed into the PJ69-4A yeast strain. 
Transformants were plated onto non-selective agar plates (SC-LW), as well as adenine 
and histidine selective agar plates (SC-ALW and SC-HLW+0.1 mM 3-AT) with ligand 
sets containing β-lactam antibiotics and several additional small molecule ligands, as 
previously mentioned (Section 3.2.2).  
 
Rational Mutagenic Approach: Results for hVDR Libraries 1 & 2 (using  
commercial Pfu) 
The non-selective plates (SC-LW) were used to determine the experimental 
library size (at the amino acid level, ~102-103 variants for each library) and 
transformation efficiency (~1.4 x 104 cfu/µg plasmid DNA for each library) of each hVDR 
library. Potentially ligand activated variants selected from the histidine selective ligand 
set 2 and LCA plates (~5 % of each experimental library) were re-tested on solid media 
plates for constitutive activity, as previously discussed.  
While most variants (~75-80 % of the tested variants) were non-functional (Figure 
3.8, circled in yellow) or constitutively active (Figure 3.8, circled in red), some showed 
ligand activated growth with LCA on histidine selective plates (Figure 3.8, circled in 
blue). A subset of these variants (22 variants) was also tested in liquid quantitation 
assays of chemical complementation. However, as shown in Figure 3.9 very little to no 
ligand activated growth was observed for these variants with LCA in histidine selective 
media. As previously observed, ligand activated growth for the wild-type hVDR was 
obtained with 10 µM LCA (blue growth profile) (Figure 3.9). Gal4 is a ligand independent 
transcription factor and was used as a positive control.  
Twelve variants from each hVDR library were submitted for sequencing (Tables  
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Figure 3.8: Rational Mutagenic Approach: Streaking for hVDR Library 1 
& 2 Variants (using commercial Pfu) Examples of non-functional variants 
are circled in yellow, of constitutively active variants are circled in red and of 
ligand activated variants are circled in blue. The controls, wild-type hVDR 
(left) and Gal4 (right) are circled in purple. 
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Figure 3.9: Rational Mutagenic Approach: hVDR Library 1 & 2 Variants 
(obtained using commercial Pfu) in Chemical Complementation  
Histidine selective media with LCA                     
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3.5 and 3.6). Overall, both libraries showed mutational diversity at the mutated positions. 
For example, positions S237, I271 and H397 from hVDR library 1 and positions Y143 
and L277 from hVDR library 2 (Tables 3.5 and 3.6) had most of the amino acids 
designed at those positions appear in the obtained variants. Despite the mutational 
diversity, again a high percentage (~55-65 %) of the sequenced variants showed frame-
shifts caused by random insertions and deletions of bases.  
 
3.3 Random Mutagenic Approach: hVDR Error-Prone PCR Libraries 
In order to overcome the five angstroms bias introduced in the rational mutagenic 
approach and to determine if selective pressure would allow for the directed evolution of 
variants with mutations outside of those explored in the designed libraries, error-prone 
PCR (epPCR) was used for the random mutagenic approach. Error-prone PCR involving 
the use of Taq polymerase was the method of choice for random mutagenesis, as this 
approach has successfully been used to engineer new receptor-ligand pairs [18]. Taq 
lacks proof-reading capabilities, hence the high number of random errors [17, 19]. In this 
epPCR approach, MnCl2 was used as a method to control the fidelity of the polymerase 
[20]. Manganese is very similar in properties to magnesium, the cofactor for Taq 
polymerase. As a result, both metals compete for binding with the polymerase. 
Manganese binding decreases the fidelity of the polymerase, increasing the number of 
mutations. Various concentrations of MnCl2 (2-500 µM) were used to amplify the hVDR 
LBD (full insert cassette) via PCR.   
For each hVDR library, the full insert cassette, the digested background plasmid 
(pGBDhVDRBackground), and the coactivator plasmid (pGAD10BAACTR) were 
transformed into the PJ69-4A yeast strain. Transformants were plated onto non-selective 
agar plates (SC-LW), as well as adenine and histidine selective agar plates (SC-ALW 















additional small molecule ligands, as previously mentioned (Section 3.2.2).     
 
 Random Mutagenic Approach: Results for hVDR Error-Prone PCR Libraries  
The experimental library size at the amino acid level (~102 variants for each 
library) and transformation efficiency (~103-104 cfu/µg plasmid DNA for each library) of 
each hVDR library were determined using the non-selective plates. Potentially ligand 
activated variants (~5-20 % of each experimental library) from the 2, 20 and 150 µM 
MnCl2 libraries were re-tested on solid media plates for constitutive activity. For each 
hVDR library, selective colonies were streaked onto non-selective plates (SC-LW), as 
well as adenine and histidine selective plates (SC-ALW and SC-HLW+0.1 mM 3-AT) 
with and without ligand (data not shown). A subset of variants was also tested in liquid 
quantitation assays of chemical complementation. However, compared to the wild-type 
hVDR no variant had increased sensitivity for LCA (~EC50>10 µM) in histidine selective 
media. Again, ligand activated growth for the wild-type hVDR was obtained with 10 µM 
LCA (blue growth profile) and as expected, Gal4, the positive control grew with and 
without ligand at an optical density of ~0.5 in histidine selective media (green growth 
profile), as shown in Figure 3.10.   
Twenty variants were submitted for sequencing. As expected, an overall increase 
in mutations was observed with increasing concentration of MnCl2 (Table 3.7). In 
addition, the number of frame-shifts was reduced drastically (compared to previous 
sequencing results), where only ~10 % of the sequenced variants had frame-shifts due 
to random insertions and deletions of bases.  
 A comparison of the variants obtained from the two mutagenic approaches tried 
thus far suggested that the rational libraries contained a large number of mutations at 
once (seven target residues), over-challenging the receptor’s tolerance and resulting in 
mostly non-functional variants. As shown in Table 3.7 and Figure 3.10, most of the  
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Figure 3.10: Random Mutagenic Approach: hVDR Error-Prone PCR 
Variants in Chemical Complementation  




variants obtained from the epPCR libraries contained two or three mutations and ligand 
activated growth profiles similar to that of the wild-type hVDR were observed for these 
variants.  As a result, we predict that smaller libraries with fewer residues chosen for 
mutagenesis would be a better approach for discovering functional variants with novel 
properties. 
 
3.4 Rational Mutagenic Approach: hVDR Subset Libraries B, C, E & F 
 In an attempt to explore hVDR libraries 1 & 2 further, four smaller subset libraries 
(hVDR libraries B, C, E & F) were constructed. In this case, one to two residues from 
each library were targeted for mutagenesis at a time (Figure 3.11). The variants of each 
hVDR library were constructed using oligonucleotides containing randomized 
degenerate codons at the chosen mutation sites, as previously described (Tables 3.8, 
3.9, 3.10 and 3.11). For each library, the full insert cassette, the digested background 
plasmid (pGBDhVDRBackground), and the coactivator plasmid (pGAD10BAACTR) were 
transformed into the PJ69-4A yeast strain. Transformants were plated onto non-selective 
agar plates (SC-LW), as well as adenine and histidine selective agar plates (SC-ALW 
and SC-HLW+0.1 mM 3-AT) with ligand sets containing β-lactam antibiotics and several 
additional small molecule ligands, as previously mentioned (Section 3.2.2).  
 
Rational Mutagenic Approach: Results for hVDR Subset Libraries B, C, E & F 
The non-selective SC-LW plates were used to determine the experimental library 
size at the amino acid level and transformation efficiency of hVDR libraries B, C, E & F. 
The library size for the various libraries was ~1.6 x 103 variants, with a transformation 
efficiency of ~2.9 x 104 cfu/µg plasmid DNA for each library. Due to the small size of 
these subset libraries (<200 at amino acid and nucleotide level), complete library 











ligand plates (~0.3-1.8% of each experimental library) were re-tested on solid media 
plates for constitutive activity, as previously discussed (data not shown). A subset of 
variants was also tested in liquid quantitation assays of chemical complementation.  
One variant from hVDR library B, BS4, showed ligand activated growth with LCA 
in histidine selective media at 100 nM, drastically showing approximately a 100-fold 
increase in sensitivity compared to the wild-type receptor (EC50= 29 nM and 6-fold 
activation vs. ~EC50> 10 µM  and 4-fold activation) (Figure 3.12, red growth profile vs. 
blue growth profile). Furthermore, this variant showed ligand activated growth with a 
novel small molecule, cholecalciferol, at 10 µM with a 4-fold activation in histidine 
selective media, as shown in Figure 3.13 (red growth profile). Cholecalciferol is a 
precursor in the 1, 25(OH)2D3 biosynthetic pathway and does not activate the wild-type 
hVDR, as shown in Figure 3.13 by the blue line.  
 
3.5  hVDR Variant BS4 Binds and Activates in Response to A Novel Small 
Molecule Ligand: Characterization in Mammalian Cell Culture Assays 
To determine whether the results obtained in yeast with variant BS4 were 
consistent with mammalian cell culture assays, the variant and the wild-type hVDR were 
cloned into a mammalian expression plasmid, pCMX (with a cytomegalovirus promoter), 
and transfected into human embryonic kidney 293T (HEK 293T) cells along with the 
p17*4TATALuc (containing a luciferase gene under the control of four Gal4 response 
elements) reporter plasmid (as described by Taylor et al.) [2]. Cell culture assays were 
performed with LCA and chole, where luciferase activity would be an indication of a 
small molecule binding and activating the variant. The wild-type hVDR (which has 
previously been shown to display activation at 100 µM) and variant BS4 displayed EC50 
values of >32 µM and 3 µM, and <10- and 34-fold activations respectively, with LCA as 
shown in Figure 3.14. BS4 displayed an EC50 value of 4 µM and a 25-fold activation with  
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Figure 3.12: Rational Mutagenic Approach: hVDR Subset Library B 
Variant BS4 in Chemical Complementation  




Figure 3.13: Rational Mutagenic Approach: hVDR Subset Library B Variant 
BS4 in Chemical Complementation  
Histidine selective media with chole
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 Figure 3.14: Rational Mutagenic Approach: hVDR Subset Library B  




Figure 3.15: Rational Mutagenic Approach: hVDR Subset Library B 
Variant BS4 in Mammalian Cell Culture Assay with chole  
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chole, as shown in Figure 3.15. The mammalian cell culture data confirms that we 
engineered a hVDR variant that is activated by lithocholic acid with enhanced sensitivity 
in comparison to the wild-type hVDR, and that this variant is also activated by the novel 
small molecule, cholecalciferol, which does not activate the wild-type hVDR. 
Several variants from each hVDR subset library were submitted for sequencing 
(Tables 3.12, 3.13, 3.14 and 3.15). Overall, the subset libraries showed poor mutational 
diversity suggesting that the targeted positions do not tolerate much change. The BS4 
variant from hVDR library B contained an undesigned mutation, C410Y. Interestingly, 
residue C410 was not one of the positions chosen for mutation in the designed libraries, 
yet through the power of genetic selection with chemical complementation, this variant 
was obtained in the designed libraries numerous times. This variant will be explored 
further in the next chapter. 
 
3.6 Summary 
To gain further insight into the role of residues important for the stability and 
function of the human vitamin D receptor (hVDR), as well as the types of chemical and 
physical changes that these and other residues in the receptor’s ligand binding domain 
(LBD) can tolerate, a mutational analysis of the hVDR’s LBD was performed. Previous 
structural and mutational work on the hVDR was used to rationally design two hVDR 
libraries using randomized codons at chosen positions, while error-prone PCR allowed 
us to create libraries of variants using random mutagenesis. All of the variants obtained 
were tested with small molecule ligands of interest, including cholecalciferol and β-
lactam antibiotics, using chemical complementation. A variant, hVDRC410Y, that is 
activated by lithocholic acid with a 100-fold enhanced sensitivity in comparison to the 
wild-type hVDR, and is also activated by the novel small molecule ligand, cholecalciferol, 
























3.7 Materials and Methods 
Ligands 
Amoxicillin, cloxacillin, penicillin G, ampicillin, oxacillin, -1-oxo-pyrenebutyric 
acid, cholecalciferol and resveratrol were purchased from Sigma-Aldrich (St. Louis, MO). 
17-β-estradiol, hexestrol, 9-cis retinoic acid and lithocholic acid were purchased from MP 
Biomedicals, LLC (Solon, OH). 10 mM stocks of all ligands were made with 80 % 
ethanol: 20 % dimethyl sulfoxide (DMSO) and stored at 4 °C. 
 
Hybridization and PCR to Create Full Insert Cassettes for hVDR Libraries 1 & 2 
For each hVDR library, 100 ng of each oligonucleotide (Operon, Huntsville, AL) 
was combined in a PCR tube with 10X Pfu buffer, dNTPs, Pfu polymerase and 125 ng of 
the corresponding forward and reverse primers (Operon, Huntsville, AL). Cassettes were 
created via PCR using the following thermocycler program: 95 ºC 3 minutes, 95 ºC 1 
minute, 60 ºC 1 minute, 72 ºC 2 minutes, repeat 15 cycles, 95 ºC 1 minute, 45 ºC 1 
minute, 72 ºC 4 minutes, repeat 15 cycles, 72 ºC 5 minutes. The full insert cassette 
(1096 bp) for each library was created via PCR using the same thermocycler program 
and the following primers: 5’-atg atc ctg aag cgg aag gag gag-3’ and 5’- tga cag gct gtg 
ccc caa agt c-3’ (Operon, Huntsville, AL). The full insert cassettes were purified using 
the QIAprep® Spin Miniprep Kit (Qiagen, Valencia, CA).  
 
 Construction of a hVDR Background Plasmid 
A hVDR background plasmid was constructed to decrease the expression of the 
wild-type hVDR in the designed libraries. SacII and KpnI restriction sites were introduced 
into the pGBDhVDR yeast expression plasmid (discussed in Chapter 2) towards the 
beginning and end of the hVDR gene, respectively, using site-directed mutagenesis 
(Stratagene, Santa Clara, CA) to create the pGBDhVDRSacIIKpnI plasmid. This plasmid 
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was digested with SacII and KpnI, removing a portion of the wild-type hVDR gene.  A 
145 bp segment of random DNA (‘junk’) from a pMSCVeGFP plasmid was amplified via 
PCR (55 ºC as the annealing temperature) using 125 ng of the following primers: 5’-atc 
ccc cgc ggg ggt ctt tca tgg gta aca gtt tct-3’ and 5’-gcc ggg tac ccg ctg tcc ata atg aac tat 
ttc agg-3’ (Operon, Huntsville, AL), digested and ligated between the SacII and KpnI 
sites in the pGBDhVDRSacIIKpnI plasmid. The underlined sequences denote SacII and 
KpnI restriction sites, respectively. The ligation was transformed into Z-competent™ XL-
1 Blue Escherichia coli (E.coli) cells (Zymo, Orange, CA).  When expression of the 
resulting plasmid, pGBDhVDRBackground, takes place three STOP codons are 
translated, resulting in a non-functional protein. Therefore background with the wild-type 
hVDR is reduced in the libraries. All DNA was purified using the QIAprep® Spin Miniprep 
Kit (Qiagen, Valencia, CA). The pGBDhVDRBackground plasmid was sequenced for 
confirmation (Operon, Huntsville, AL).  
 
Yeast Transformation Using the PJ69-4A Strain  
For each hVDR library, using the TRAFCO yeast transformation protocol, 1 µg of 
the full insert cassette and 0.3 µg of the yeast expression plasmids, 
pGBDhVDRBackground (containing a tryptophan marker, digested) and 
pGAD10BAACTR (containing the Gal4 AD fused to ACTR and a leucine marker), were 
transformed into the yeast strain PJ69-4A [21]. Transformants were plated onto non-
selective agar plates (SC-LW), as well as adenine and histidine selective agar plates 
(SC-ALW or SC-HLW+0.1 mM 3-AT) with 10 µM of ligand set 1 (amoxicillin, cloxacillin, 
penicillin G, 17-β-estradiol and -OPBA), 10 µM of ligand set 2 (ampicillin, oxacillin, 
hexestrol, 9-cis retinoic acid, and resveratrol) and LCA (10 µM) and chole (10 µM) 
individually. Plates were incubated at 30 ºC for 3-4 days.  
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Liquid Quantitation Assays of Chemical Complementation in Yeast 
Variants obtained from the yeast transformation were grown overnight in non-
selective SC-LW media, at 30 ºC with shaking at 300 rpm. A 4:1 ratio of selective media 
(SC-ALW or SC-HLW+0.1 mM 3-AT with and without ligand at varying concentrations): 
cells (yeast resuspended in water) were aliquoted into 96-well plates. Plates were then 
incubated at 30 ºC with shaking at 170 rpm for 48 hours, with optical density readings at 
a wavelength of 630 nm (OD630) taken at 0, 24 and 48 hours. All data points represent 
the mean of at least duplicate experiments and the bars indicate standard deviation. The 
lowest ligand concentration data points for all plots contain no ligand. EC50 values were 
calculated using GraphPad Prism and a non-linear regression extrapolation. 
 
Using Klenow to Create Full Insert Cassettes for hVDR Libraries 1 & 2 
Followed a revised version of the protocol proposed by Holowachuk and Ruhoff 
[17]. 500 ng of each oligonucleotide (Operon, Huntsville, AL), NEBuffer 2 (New England 
Biolabs, Ipswich, MA) and distilled water were combined in a tube, heated to 95 ºC for 5 
minutes, 50 ºC for 5 minutes and cooled to 25 ºC. After this hybridization step, Klenow 
polymerase (New England Biolabs, Ipswich, MA) and dNTPs were added, and the 
mixture was cooled at 25 ºC for 15 minutes and heated to 75 ºC for 20 minutes to extend 
the oligonucleotides. Cassettes were then combined and amplified via PCR, with 10X 
Pfu buffer, dNTPs, Pfu polymerase and 125 ng of the corresponding forward and 
reverse primers (Operon, Huntsville, AL).  
 
Error-Prone PCR 
 A section of the hVDR ligand binding domain (LBD) (full-insert cassette) was 
amplified from the pGBDhVDR yeast expression plasmid via PCR (55 ºC as the 
annealing temperature) using 500 ng of the following primers: 5’-atg atc ctg aag cgg aag 
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gag gag-3’ and 5’- tga cag gct gtg ccc caa agt c-3’ (Operon, Huntsville, AL), in addition 
to 10x Taq buffer, dNTPs, MgCl2, MnCl2 and Taq polymerase (Omega Bio-Tek, 
Norcross, GA). The full insert cassettes were purified using the QIAprep® Spin Miniprep 
Kit (Qiagen, Valencia, CA). 
 
Hybridization and PCR to Create Full Insert Cassettes for hVDR Libraries B, C, E & F 
For each hVDR library, 100 ng of each oligonucleotide (Operon, Huntsville, AL) 
was combined in a PCR tube with 10X Pfu buffer, dNTPs, Pfu polymerase and 125 ng of 
the corresponding forward and reverse primers (Operon, Huntsville, AL). For hVDR 
libraries B & F the following primers were used: 5’- gat cct gaa gcg gaa gga gg-3’ and 5’- 
gtc cag gca ggg tgg cca gaa cgg gtg ggc aca aag gat gga cta gtt cag gag atc tca ttg cca 
aac act tcg ag-3’. For hVDR libraries C & D the following primers were used: 5’- gat cct 
gaa gcg gaa gga gg-3’ and 5’- gtc cag gca ggg tgg cc-3’. The full insert cassette for each 
library (1014 bp) was created using the following thermocycler program: 95 ºC 1 minute, 
59 ºC 1 minute, 72 ºC 2 minutes, repeat 20 cycles, 95 ºC 1 minute, 56.6 ºC 1 minute, 72 
ºC 2 minutes, repeat 20 cycles, 72 ºC 3 minutes. The full insert cassettes were purified 
using the QIAprep® Spin Miniprep Kit (Qiagen, Valencia, CA).  
 
Construction of Mammalian Expression Plasmids  
The Gal4 DBD fused to full-length hVDR (GBDhVDR) as well as the 
hVDRC410Y variant (GBDhVDRC410Y), was amplified from the respective pGBD yeast 
expression plasmid via PCR (55 ºC as the annealing temperature) using 125 ng of the 
following primers: 5’-tcc ccg cgg atg aag cta ctg tct tct atc gaa caa g-3’ and 5’- aag gaa 
aaa agc ggc cgc tca gga gat ctc att gcc aaa ca-3’ (Operon, Huntsville, AL). The 
underlined sequences denote SacII and NotI restriction sites, respectively. The fusion 
constructs and mammalian expression plasmid, pCMX, which contains a 
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cytomegalovirus (CMV) promoter, were digested with SacII and NotI, ligated, and 
transformed into Z-competent™ XL-1 Blue Escherichia coli (E.coli) cells (Zymo, Orange, 
CA). The resulting plasmids were pCMXGRhVDR and pCMXGRhVDRC410Y. All DNA 
was purified using the QIAprep® Spin Miniprep Kit (Qiagen, Valencia, CA). The 
pCMXGRhVDR and pCMXGRhVDRC410Y plasmids were sequenced for confirmation 
(Operon, Huntsville, AL).  
 
Mammalian Cell Culture Assays 
Human embryonic kidney 293T cells (HEK 293T, ATCC, USA) were transfected 
with the pCMX mammalian expression plasmids discussed above, along with the 
p17*4TATAluc and pCMXβ-gal reporter plasmids as described by Taylor et al., using 
Lipofectamine 2000 (Invitrogen, Carlsbad, CA) as the cationic lipid [2]. p17*4TATAluc 
contains the Renilla luciferase gene under the control of four Gal4 response elements, 
while pCMXβ-gal contains the β-galactosidase gene under the control of the mammalian 
CMV promoter. Cells were harvested ~36-48 hours after the addition of ligand at varying 
concentrations, and analyzed for luciferase and β-galactosidase activity. All data points 
represent the mean of triplicate experiments normalized against β-galactosidase activity 
and the bars indicate standard deviation. The lowest ligand concentration data points for 
all plots contain no ligand. EC50 values were calculated using GraphPad Prism and a 
non-linear regression extrapolation. Fold activations were calculated by dividing the 
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ENGINEERING THE HVDRC410Y VARIANT AND INVESTIGATING THE 





4.1 Engineering hVDRC410Y and Investigating hVDR Residue C410 
To investigate the structure-function relationships between the human vitamin D 
receptor (hVDR) and its ligands, as well as gain insight into the role and tolerance of 
specific residues, a mutational analysis of residues in the hVDR’s ligand binding domain 
(LBD) was performed. As discussed in Chapter 3, libraries of hVDR variants were 
engineered by methods of rational and random mutagenesis and tested using chemical 
complementation. One variant containing an undesigned mutation at the C410 position 
to a tyrosine, hVDRC410Y, displayed a 100-fold increase in sensitivity towards a known 
hVDR ligand, lithocholic acid (LCA), in comparison to the wild-type receptor. This variant 
was also activated by a novel small molecule ligand, cholecalciferol (chole), whereas the 
wild-type receptor is not (Figure 4.1).  
In this work, several approaches were taken to investigate the hVDRC410Y 
variant and residue C410 further. In an attempt to discover a variant with even higher 
sensitivity for LCA and/or chole, the C410Y variant was subjected to random 
mutagenesis via error-prone PCR (epPCR). Residue C410 does not line the hVDR’s 
ligand binding pocket (LBP) and as a result does not make direct contacts with the 
natural ligand, 1, 25(OH)2D3, yet surprisingly contributes towards enhanced activation 
with LCA and chole. In-silico docking of these ligands with C410Y was performed, in 
quest of gaining structural insight into this variant. The mutational tolerance of residue 
C410 was also investigated, using site-directed mutagenesis to change the residue to 
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Figure 4.1: Structures of hVDR Ligands and Molecules of Interest 
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amino acids of varying chemical and physical properties. Lastly, the effects of combining 
the C410Y mutation with other hVDR mutations previously obtained in our lab were 
explored. 
 
4.2 Engineering hVDRC410Y: Error-Prone PCR Libraries 
The C410Y variant was obtained from one of the libraries created in Chapter 3 
using the rational mutagenic approach. Interestingly, residue C410 was not one of the 
positions chosen for mutation in the designed libraries, yet through the power of 
selection in the chemical complementation method, this variant was obtained in the 
designed libraries numerous times. To determine whether selective pressure would 
allow for the directed evolution of a variant with further enhanced sensitivity for LCA 
and/or chole, while overcoming the five angstroms bias introduced in the rational 
mutagenic approach, the C410Y variant was used as the template for random 
mutagenesis via epPCR using Taq polymerase. As previously discussed in Chapter 3, 
Taq polymerase lacks proof-reading capabilities and the addition of MnCl2 can be used 
to control the fidelity of the enzyme, with higher concentrations of MnCl2 resulting in 
higher numbers of mutations [1, 2]. Various concentrations of MnCl2 (2-200 µM) were 
used to amplify the hVDRC410Y LBD (full insert cassette) via PCR. 
For each epPCR library, the full insert cassette, the digested background plasmid 
(pGBDhVDRBackground, containing a tryptophan marker and the Gal4 DNA Binding 
Domain (GBD) fused to a portion of the hVDR followed by a ‘junk’ sequence), and the 
coactivator plasmid (pGAD10BAACTR, containing a leucine marker and the Gal4 
activation domain (GAD) fused to the activator for thyroid and retinoid receptors (ACTR)) 
were transformed into the PJ69-4A yeast strain. Transformants were plated onto non-
selective synthetic complete agar plates lacking leucine and tryptophan (SC-LW) to 
select for both plasmids, and to determine whether homologous recombination between 
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the insert cassette and background plasmid occurred. The PJ69-4A yeast strain contains 
the HIS3 and ADE2 genes, essential genes in the corresponding histidine or adenine 
biosynthetic pathway, under the control of Gal4 response elements. As a result, 
transformants were also plated onto adenine and histidine selective agar plates (SC-
ALW and SC-HLW+0.1 mM 3-AT) containing individual ligands.  
Since the C410Y variant displayed ligand activated growth with LCA at 100 nM 
and with chole at 10 µM in histidine selective media when tested in chemical 
complementation, and the goal was to obtain a variant with further enhanced sensitivity, 
individual selective plates containing 10 nM LCA and 1 µM chole were used (Chapter 3, 
Figures 3.12 and 3.13). In addition to the ligand sets discussed in Chapter 3 (section 
3.2.2), individual selective plates containing 10 µM deoxycholic acid (DCA) and cholic 
acid (CA) were used. Like LCA, DCA and CA are bile acids; their structures being 
extremely similar to each other. Compared to LCA, DCA has one additional hydroxyl 
group while CA has two additional hydroxyl groups (Figure 4.1). Besides increasing the 
sensitivity of C410Y for LCA and chole, part of the goal was to determine if a variant 
could be engineered to activate in response to another novel small molecule ligand. Due 
to the structural similarities between LCA, DCA and CA, activation with these molecules 
can provide significant insight into specific receptor-ligand interactions, perhaps on the 
importance of hydrogen bonding for the stability and function of the receptor. 
 
 Engineering hVDRC410Y: Results for Error-Prone PCR Libraries  
 The non-selective (SC-LW) plates were used to determine the experimental 
library size and transformation efficiency of each C410Y library. The transformations 
produced a library size of ~103 variants for each library, with transformation efficiencies 
of ~105 cfu/µg plasmid DNA per library. Unfortunately, no ligand activated variants were 
obtained on the selective plates with ligand.  
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Homologous recombination between the insert cassette and background plasmid 
occurred successfully for each C410Y epPCR library, as variants were obtained on non-
selective plates. To confirm that the lack of selective ligand activated variants was not 
due to an unreasonable number of mutations being introduced into the C410Y template, 
ten non-selective variants (several from each library) were submitted for sequencing. 
Mutational frequencies similar to those obtained for the hVDR epPCR libraries created in 
Chapter 3 were observed, and as expected, an overall increase in mutations was 
observed with increasing concentration of MnCl2. These results suggest that for these 
libraries ligand activated variants were not obtained due to the lack of a variant with 
enhanced sensitivity for LCA/chole or activation with any of the other ligands tested, and 
not due to nonsense mutations or truncated proteins.  
 
4.3 hVDR Residue C410 and In-Silico Docking of wthVDR and hVDRC410Y 
Structurally, cysteines have been shown to play an important role in the 
maintenance of protein conformation, primarily due to the formation of strong disulfide 
bonds that contribute to protein stability. Disulfide bonds are covalent bonds formed by 
the coupling of two thiol groups. Early biochemical experiments on the hVDR suggested 
that amino acids with sulfhydryl-containing side chains may play a crucial role in ligand 
binding, potentially by contributing to the proper conformation of the LBP [3, 4]. However 
in the case of the C410Y variant a cysteine residue was mutated to a tyrosine, resulting 
in enhanced activity with a known ligand and activation with a novel small molecule.  
Residue C410 is located in the loop between helices 11 and 12 of the hVDR’s 
LBD and is part of a compact hydrophobic core involving residues from helix 3n (L221 
and L224), helix 3 (L227) and helix 11 (L404) (Figure 4.2a) [5, 6]. In the crystal structure 
of the hVDR with its natural ligand, 1, 25(OH)2D3, this residue is 8.48 Å from the 25-  
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Figure 4.2: hVDR Residue C410. Cysteine 410 is part of a hydrophobic core 
and is 8.48 Å from 1,25(OH)2D3’s 25-hydroxyl group. Ligand (Cyan), hVDR 
residues (Purple), AF-2 Domain (Red Helix), hydrogen bonds (Red Lines), 
distance measured (Black Line), PDB:1DB1 
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hydroxyl group of the ligand and is not involved in direct contacts with the small molecule 
(Figure 4.2b) [5]. Interestingly, cysteine 410 also happens to be one of three residues 
(L378, C403, and C410) that differ in the C-terminal regions of the rat VDR (rVDR) and 
hVDR LBDs [7-10]. Along with C403, this residue has been implicated to be involved in 
mediating opposing effects in the two species despite the fact that neither of these 
residues is close enough to make direct contacts with the ligand [7-12]. Specifically, the 
small molecule TEI-9647 (a 1,25(OH)2D3 derivative) has been shown to have an 
antagonistic effect on the hVDR, while an agonistic effect has been observed on the 
rVDR (Figure 4.1).  
Molecular models with 1, 25(OH)2D3 have shown that the R-groups of the 
corresponding rVDR loci (S399 and N406) form additional hydrogen bonds not formed 
by the hVDR C403 and C410 thiol groups, providing helix 12 with additional stability and 
enhanced rVDR-coactivator interactions thus gene activation [8, 10, 12, 13]. Recent 
work on the VDR has elucidated the mechanisms underlying the opposing effects of TEI-
9647 between the hVDR and rVDR [7, 10, 14]. Work by Kakuda et al. indicates that for 
the hVDR, TEI-9647 hydrogen bonds to residue H305 resulting in a conformational 
change of the receptor, such that residue C403 or C410 are shifted towards the ligand. A 
covalent bond between the thiol group of C403 or C410 and the TEI-9647 25-methylene 
group is then formed, along with the disruption of hydrophobic contacts with helix 12 
thus gene repression [14].  
To visualize the structural impact of the C410Y mutation on the hVDR, in-silico 
docking of 1, 25(OH)2D3, LCA and chole with the wild-type hVDR and hVDRC410Y 
was performed using AutoDock Vina [15]. In-silico docking programs such as AutoDock 
Vina predict how well a given molecule will fit into the binding site of a target structure. In 
general docking consists of two steps; sampling of the ligand’s possible conformations in 
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the binding site, and scoring of the poses [16, 17]. During docking simulations with 
AutoDock Vina, the ligand is flexible while the protein is held rigid. When the wild-type 
hVDR and variant C410Y docked structures were superimposed, as expected only slight 
structural changes were observed. For 1, 25(OH)2D3 a small upward shift of the ligand 
(docked into the variant) in the pocket resulted in closer proximity of the aliphatic chain 
25-hydroxyl group to residue H305, an important hydrogen bonding residue in the hVDR 
(Figure 4.3a). For LCA the ring system of both docked structures overlap with each 
other, however the side chain of the ligand docked into the variant is curved towards the 
center and away from the end of the pocket consisting of residue C410. In this case the 
carboxyl group on the side chain is positioned further from two important hydrogen 
bonding residues (H305 and H397) (Figure 4.3b). This is surprising due to the enhanced 
activation observed for C410Y with LCA. The docked structure for chole with the variant 
shows a very similar conformation, compared to the natural ligand docked into the wild-
type hVDR (Figure 4.3c). These theoretical models may not accurately represent the 
positioning of the ligands in the pocket, nevertheless we can conclude that the increased 
bulkiness at the C410 position, with a tyrosine substituting a cysteine, may be 
contributing to a shift (upwards in the pocket) and/or repositioning (curvature into the 
center of the pocket) of the ligand. The subtle and contradicting structural effects of 
residue C410 on the hVDR limit our conclusions to these generalizations, yet the effect 
on ligand specificity and activation continue to be surprising, considering how distant this 
residue is located within the hVDR LBD.  
 
4.4 Mutational Tolerance of Residue C410  
Naturally, the fact that residue C410 was not targeted in the designed libraries 
and that the mutation C410Y resulted in a unique activation profile with both LCA and 
chole led to further investigation of this position; particularly on the role and tolerance of  
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Figure 4.3: In-silico Docking of wthVDR and hVDRC410Y with Various 
Ligands hVDR residues (Purple), PDB:1DB1  
(a) Wild-type docked structure: 1, 25(OH)2D3 (Cyan),  
      Variant docked structure: 1, 25(OH)2D3 (Yellow)  
(b) Wild-type docked structure: LCA (Cyan),  
      Variant docked structure: LCA (Red)  
(c) Wild-type docked structure: 1, 25(OH)2D3 (Cyan),  
Variant docked structure: chole (Pink)
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this residue on activation of the receptor by various ligands. Gaining an understanding 
on the tolerance of specific residues in the hVDR’s LBD provides insight into the 
structural and functional parameters of this domain. Insight from an evolutionary 
perspective can also be gained. For example, in this specific case evolution selected a 
cysteine at position 410 of the hVDR and an asparagine for the rat ortholog (rVDR). This 
may be due to the presence of different metabolites in these organisms, such that an 
asparagine may accommodate the metabolites found in rat versus those found in 
mammalian cells. By investigating the tolerance of this position, information on what 
types of amino acids are preferred, as well as which ones contribute towards the 
activation of the receptor can be gained. This knowledge can be applied towards the 
development of small molecules for therapeutic use, especially non-natural ligands 
which may not contribute to the ‘traditional or common’ interactions but may compensate 
for them in other ways. 
In order to determine whether (1) the enhanced C410Y activity was specifically 
due to the presence of a tyrosine, (2) a physical or chemical property of the residue was 
responsible for the observed activation profiles (e.g. increased bulkiness and hydrogen 
bonding capability) and (3) another amino acid would display a similar activation profile 
as the C410Y variant, this residue was mutated to amino acids of varying polarity, shape 
and volume (e.g. phenylalanine, alanine, serine, asparagine, tryptophan, histidine, 
leucine, methionine, threonine and lysine) using site-directed mutagenesis and the yeast 
expression plasmid, pGBDhVDR, as the template. Each variant was transformed into the 
PJ69-4A yeast strain along with the coactivator plasmid (pGAD10BAACTR) and tested 
using chemical complementation, where yeast growth would be an indication of a small 
molecule binding and activating the variant (ligand activated growth). Overall, no drastic 
changes would have been expected in the behavior of these variants due to the location 
of the residue in the LBD. However, in looking at the crystal structure, the presence of a 
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cavity at the end of the pocket containing residue C410 suggests that the increase in 
bulk at the C410 position may attribute to the filling of this cavity and possibly leading to 
the molecular interactions necessary for the enhanced and novel activation observed 
with LCA and chole, respectively. 
 
 Mutational Tolerance of Residue C410: Results for hVDRC410 Variants in 
Chemical Complementation 
When tested in liquid quantitation assays of chemical complementation with 1, 
25(OH)2D3, LCA and chole in histidine selective media (SC-HLW + 0.1 mM 3-AT), most 
of the C410 variants behaved similar to the wild-type hVDR (Figures 4.4a-c). More 
specifically, with 1, 25(OH)2D3 ligand activated growth was observed for C410F, 
C410A, C410S, C410N, C410H, C410L, C410M, C410T, and C410K at 10 nM with an 
~EC50>10 nM, indicating a wide range of tolerance at this position for different types of 
residues (Figure 4.4a). Ligand activated growth was not observed for variant C410W, 
which could imply that excessive bulk is not tolerated at this position (Figure 4.4a). 
Overall, position C410 is fairly tolerant of mutations with the variants studied displaying 
profiles similar to that of the wild-type receptor and C410Y (~EC50>10 nM vs. EC50≈ 2 
nM) but with a 10-fold decrease in sensitivity when tested with 1,25(OH)2D3 (Figure 
4.4a). Despite residue C410’s distance from 1, 25(OH)2D3, the fact that this position 
tolerated a wide range of amino acids including alanine was surprising, indicating that 
perhaps this residue does not contribute to the activation of the hVDR by its natural 
ligand; as seen with the rat VDR (rVDR) where the presence of an asparagine at this 
position results in comparable activation with 1, 25(OH)2D3. However, there seems to 
be some limitation to this tolerance as observed with C410W. Tryptophan has the largest 
volume among all amino acids (227.8 Å3) [18]. The lack of ligand activation for this 
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variant and 1, 25(OH)2D3 may be due to the significantly increased bulkiness at the 
C410 position, which may disrupt residue packing within the ligand binding domain. 
Despite the fact that with 1, 25(OH)2D3 a range of tolerance was observed at 
the C410 position, the same trend does not seem to be observed with other ligands. 
When tested with LCA, similar to the C410Y variant, C410F exhibited ligand activated 
growth at 100 nM with an EC50= 54 nM (EC50= 29 nM for C410Y) (Figure 4.4b). Similar 
to the wild-type hVDR, ligand activated growth at 10 µM with an ~EC50> 10 µM was 
observed for the rest of the C410 variants (Figure 4.4b). C410W which did not show 
growth with the natural ligand, also displayed ligand activated growth with LCA at 10 µM 
(~EC50> 10 µM), indicating that the increase of bulk and packing of the cavity at this end 
of the pocket contributes to activation with LCA (Figure 4.4b). When tested with chole, 
C410F once again exhibited a ligand activated growth profile similar to that of C410Y 
with growth at 10 µM and an ~EC50> 10 µM (Figure 4.4c). Like the wild-type hVDR, the 
rest of the C410 variants (including C410W) did not display ligand activated growth with 
chole (Figure 4.4c).  
Interestingly, as shown in this work, the presence of a tyrosine at the C410 
position results in a novel activation profile with both LCA and chole in comparison to the 
wild-type hVDR. In addition to the tyrosine, the same activation profile is observed with 
C410F, emphasizing the importance of bulkiness for activation with both ligands, as well 
as suggesting that the presence of a hydrogen bonding residue versus a hydrophobic 
one at C410 does not seem to affect the overall activity obtained with these ligands. 


















































































































1, 25(OH)2D3. As a result, the increased bulkiness at the C410 position (volumes: 
cysteine 108.5 Å3, phenylalanine 189.9 Å3, and tyrosine 193.6 Å3) may contribute 
additional contacts by decreasing the overall volume of the hVDR’s LBP, and filling the 
cavity present at that end of the pocket [18].  
 
4.5 Enhancing the Sensitivity of hVDRC410Y  
Previously in our lab via random mutagenesis, a hVDR variant, H305F;H397Y, 
was engineered to activate in response to cholecalciferol (Ousley et al., manuscript 
submitted). Interestingly, both of the residues mutated in this variant and residue C410 
are positioned on the same end of the hVDR’s LBP (Figure 4.2b). Additionally, the 
aliphatic chain of 1, 25(OH)2D3 which is also positioned on this end of the pocket upon 
binding the hVDR has been the main target of chemical modifications during drug 
development, as the cycloalkane rings have not been successfully changed without loss 
of ligand activation (Figure 4.2b) [5]. Receptor activation has been maintained or 
enhanced with many of the developed analogs and the currently discussed hVDR 
variants, suggesting that receptor-ligand interactions in this region of the LBP have some 
flexibility in terms of tolerating structural variations.  
To determine the effects of combining the H305F, H397Y and C410Y mutations 
on ligand activation, different combinations of these mutations were introduced into the 
hVDR. Mammalian expression plasmids (pCMX, with a cytomegalovirus promoter) 
containing the variants under investigation were transfected into human embryonic 
kidney 293T (HEK 293T) cells along with the p17*4TATALuc (containing a luciferase 
gene under the control of four Gal4 response elements) reporter plasmid (as described 
by Taylor et al.) [19]. Cell culture assays were performed with 1, 25(OH)2D3, LCA and 
chole, where luciferase activity would be an indication of a small molecule binding and 
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activating the variant. Overall, an increase in sensitivity for LCA and chole was expected 
for these variants as the hypothesis that the combination of the H305F, H397Y and 
C410Y mutations would have an additive effect on the activation of the hVDR was 
developed. 
 
Enhancing the Sensitivity of hVDRC410Y: Results for hVDR Variants in  
Mammalian Cell Culture Assays 
The variants H305F and C410Y showed EC50 values of 4 nM and 1 nM with 
1,25(OH)2D3, and ~10 µM and 3 µM with LCA, respectively. The variant H305F;C410Y 
displayed slightly higher sensitivity for 1,25(OH)2D3 and enhanced sensitivity for LCA 
(~10-fold compared to C410Y), compared to the other variants tested with an EC50< 1 
nM and a 54-fold activation and an EC50= 0.3 µM and a 28-fold activation, respectively 
(Figures 4.5a and 4.5b, and Table 4.1). With chole, the variants H305F and C410Y 
showed EC50 values of 2 µM and 4 µM, respectively. H305F;H397Y and H305F;C410Y 
shared the same enhanced sensitivity for chole (~10-fold compared to C410Y), with an 
EC50= 0.3 µM and a 42-fold activation and an EC50= 0.2 µM and a 14-fold activation, 
respectively (Figure 4.5c and Table 4.1). Interestingly, the variant H305F;H397Y;C410Y 
displayed constitutive activity, indicating that the receptor is in an active conformation, 
with activation observed in the absence of an exogenous small molecule ligand (Figures 
4.5a-c).  
Based on these results, some of the explored mutations did have a slight additive 
effect when combined. As previously mentioned with the C410Y mutation individually, 
the enhanced activity observed for the variant H305F;C410Y may be due to the 
increased bulkiness at the H305 and C410 positions (volumes: histidine 153.2 Å3 and  
































































































contacts with the smaller molecular volume ligands [18]. For the H305F;H397Y;C410Y 
variant however, the dramatic decrease in the overall volume of the hVDR’s LBP when 
changing one residue to a phenylalanine and two to tyrosines resulted in a constitutively 
active receptor. This may potentially be due to an ‘over-stabilized’ active conformation 
and/or significantly enhanced hVDR-coactivator interactions. The results obtained with 
the hVDR variants studied thus far suggest that the end of the hVDR ligand binding 
pocket consisting of residues H305, H397 and C410 not only tolerates mutations, but is 




We have explored the effects of mutating a residue (C410) that does not line the 
human vitamin D receptor’s (hVDR) ligand binding pocket (LBP) and that as a result 
does not make direct contacts with the natural ligand. In-silico docking results of LCA 
and chole with hVDRC410Y do not show drastic changes in the ligand-receptor poses 
compared to the wild-type hVDR, yet the mutation C410Y contributes towards enhanced 
activation with both ligands. When the C410Y mutation was combined with an additional 
mutation on the same end of the LBP, H305F, the receptor’s sensitivity for these ligands 
was enhanced further, emphasizing the importance of bulkiness at this end of the pocket 
for activation with both ligands. 
Previous work on the hVDR has focused on residues lining the receptor’s ligand 
binding pocket; however the unforeseen effects of mutating residue C410 on specificity 
and activation with the ligands studied not only serve as an example of the significant 
impact distant residues can have on receptor activation with different ligands but also 
emphasize the important role physical properties of residues, such as volume, can play 
for specific ends of the LBP compared to chemical properties. Future work investigating 
 126
the effects of C410Y on ligand binding and receptor-coactivator interactions would 
provide insight into the indirect effects of this mutation on the activation of the hVDR.  
 
4.7  Materials and Methods 
Ligands 
Amoxicillin, cloxacillin, penicillin G, ampicillin, oxacillin, -1-oxo-pyrenebutyric 
acid, cholecalciferol, resveratrol and cholic acid were purchased from Sigma-Aldrich (St. 
Louis, MO). 17-β-estradiol, hexestrol, 9-cis retinoic acid, lithocholic acid and deoxycholic 
acid were purchased from MP Biomedicals, LLC (Solon, OH). 1α,25-dihydroxyvitamin D3 
was purchased from BIOMOL (Plymouth Meeting, PA). 10 mM stocks of all ligands, 
except 1α,25-dihydroxyvitamin D3, for which a 13.3 µM stock was made, were made with 
80 % ethanol: 20 % dimethyl sulfoxide (DMSO) and stored at 4 °C. 
 
Error-Prone PCR 
 A section of the hVDRC410Y LBD (full-insert cassette) was amplified from the 
pGBDhVDRC410Y yeast expression plasmid via PCR (55 ºC as the annealing 
temperature) using 500 ng of the following primers: 5’- gat cct gaa gcg gaa gga gg-3’ 
and 5’- gtc cag gca ggg tgg cca gaa cgg gtg ggc aca aag gat gga cta gtt cag gag atc tca 
ttg cca aac act tcg ag-3’ (Operon, Huntsville, AL), in addition to 10x Taq buffer, dNTPs, 
MgCl2, MnCl2 and Taq polymerase (Omega Bio-Tek, Norcross, GA). The full insert 
cassettes were purified using the QIAprep® Spin Miniprep Kit (Qiagen, Valencia, CA). 
 
Yeast Transformation Using the PJ69-4A Strain 
For each hVDR library, using the TRAFCO yeast transformation protocol, 1 µg of 
the full insert cassette and 0.3 µg of the yeast expression plasmids, 
pGBDhVDRBackground (containing the Gal4 DBD fused to a portion of the hVDR 
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followed by the ‘junk’ sequence and a tryptophan marker, digested (discussed in 
Chapter 3)) and pGAD10BAACTR (containing the Gal4 AD fused to ACTR and a leucine 
marker), were transformed into the yeast strain PJ69-4A [20]. Transformants were plated 
onto non-selective agar plates (SC-LW), as well as adenine and histidine selective agar 
plates (SC-ALW or SC-HLW+0.1 mM 3-AT) with 10 µM of ligand set 1 (amoxicillin, 
cloxacillin, penicillin G, 17-β-estradiol and -OPBA), and 10 µM of ligand set 2 
(ampicillin, oxacillin, hexestrol, 9-cis retinoic acid, and resveratrol). Selective plates 
containing 10 nM LCA, 1 µM chole, 10 µM DCA and 10 µM CA individually were also 
used. Plates were incubated at 30 ºC for 3-4 days.  
 
Liquid Quantitation Assays of Chemical Complementation in Yeast 
Transformants obtained from the yeast transformation were grown overnight in 
non-selective SC-LW media, at 30 ºC with shaking at 300 rpm. A 4:1 ratio of selective 
media (SC-ALW or SC-HLW+0.1 mM 3-AT with and without ligand at varying 
concentrations): cells (yeast resuspended in water) were aliquoted into 96-well plates. 
Plates were then incubated at 30 ºC with shaking at 170 rpm for 48 hours, with optical 
density readings at a wavelength of 630 nm (OD630) taken at 0, 24 and 48 hours. All 
data points represent the mean of at least duplicate experiments and the bars indicate 
standard deviation. The lowest ligand concentration data points for all plots contain no 
ligand. EC50 values were calculated using GraphPad Prism and a non-linear regression 
extrapolation. 
 
In-Silico Docking of Wild-type hVDR and hVDRC410Y 
  The structure of the hVDRC410Y variant was prepared in-silico using the 
program TRITON 4.0.0 (National Centre for Biomolecular Research, Czech Republic) 
and its external program MODELLER (National Centre for Biomolecular Research, 
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Czech Republic). A computational site-directed mutagenesis method, where the wild-
type protein is used for homology modeling was employed [21, 22]. The atomic 
coordinates of the crystal structure of the hVDR ligand binding domain (165-215) were 
retrieved from the Research Collaboratory for Structural Bioinformatics (RCSB) Protein 
Data Bank (PDB) (PDB ID: 1DB1) [5, 23].  
The wild-type hVDR and hVDRC410Y structures were prepared for docking 
using the UCSF CHIMERA-interactive molecular graphics program by: (1) removing the 
ligand and water molecules, (2) adding polar hydrogens, and (3) assigning Gasteiger 
charges [24]. The three-dimensional structure of each ligand was constructed and 
minimized using ChemBioDraw Ultra 11.0 and ChemBio3D Ultra 11.0 (Cambridge Soft, 
USA) [25]. AutoDockTools was used to add Gasteiger charges to each ligand structure, 
setting the partial charge property of each atom. Docking simulations were performed 
using AutoDock Vina with default parameters, such that the protein was held rigid and 
the ligand was allowed free rotation [15]. The receptor-ligand poses of lowest free 
energy of binding were analyzed further. 
 
Site-Directed Mutagenesis 
Mutations were introduced into the yeast expression plasmid, pGBDhVDR, using 
PCR (Stratagene, Santa Clara, CA) and the corresponding mutagenic primers (Operon, 
Huntsville, AL).  All plasmids were purified using the QIAprep® Spin Miniprep Kit 
(Qiagen, Valencia, CA) and sequenced for confirmation (Operon, Huntsville, AL).  
 
Construction of Mammalian Expression Plasmids  
The Gal4 DBD fused to the hVDR variants H305F, H397Y, H305F;H397Y, 
H305F;C410Y, H397Y;C410Y, and H305F;H397Y;C410Y, was amplified from the 
respective pGBD yeast expression plasmid via PCR (55 ºC as the annealing 
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temperature) using 125 ng of the following primers: 5’-tcc ccg cgg atg aag cta ctg tct tct 
atc gaa caa g-3’ and 5’- aag gaa aaa agc ggc cgc tca gga gat ctc att gcc aaa ca-3’ 
(Operon, Huntsville, AL). The underlined sequences denote SacII and NotI restriction 
sites, respectively. The fusion constructs and mammalian expression plasmid, pCMX 
(discussed in Chapter 3), were digested with SacII and NotI, ligated, and transformed 
into Z-competent™ XL-1 Blue Escherichia coli (E.coli) cells (Zymo, Orange, CA). The 
resulting plasmids pCMXGRhVDRH305F, pCMXGRhVDRH397Y, 
pCMXGRhVDRH305F;H397Y, pCMXGRhVDRH305F;C410Y, 
pCMXGRhVDRH397Y;C410Y, and pCMXGRhVDR H305F;H397Y;C410Y were purified 
using the QIAprep® Spin Miniprep Kit (Qiagen, Valencia, CA) and sequenced for 
confirmation (Operon, Huntsville, AL).  
 
Mammalian Cell Culture Assays 
Human embryonic kidney 293T cells (HEK 293T, ATCC, USA) were transfected 
with the pCMX mammalian expression plasmids discussed above, along with the 
p17*4TATAluc and pCMXβ-gal reporter plasmids (discussed in Chapter 3) as described 
by Taylor et al., using Lipofectamine 2000 (Invitrogen, Carlsbad, CA) as the cationic lipid 
[19]. Cells were harvested ~36-48 hours after the addition of ligand at varying 
concentrations, and analyzed for luciferase and β-galactosidase activity. All data points 
represent the mean of triplicate experiments normalized against β-galactosidase activity 
and the bars indicate standard deviation. The lowest ligand concentration data points for 
all plots contain no ligand. EC50 values were calculated using GraphPad Prism and a 
non-linear regression extrapolation. Fold activations were calculated by dividing the 
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INVESTIGATING THE ROLE AND MUTATIONAL TOLERANCE OF TYROSINES 143 




5.1 Tyrosines and the Two Anchoring Ends of the hVDR’s Ligand Binding Pocket 
Most nuclear receptors and their ligands are involved in forming key molecular 
interactions that are crucial for the activation and function of the receptor. These 
interactions include hydrophobic and electrostatic interactions (e.g. Van der Waals and 
hydrogen bonding). For example, 17-β estradiol forms two hydrogen bonds with residues 
located on opposite ends of the estrogen receptor’s ligand binding pocket [1].  Glutamate 
353, arginine 394 and a water molecule form a network of hydrogen bonds with the 3-
hydroxyl group of estradiol, while histidine 524 on the other end of the pocket forms a 
hydrogen bond with the 17-hydroxyl group of the ligand [1, 2]. Hydrogen bonding 
residues are important, as they often anchor ligands in the pockets of nuclear receptors 
[3, 4]. Additionally, they contribute significantly to the three-dimensional structures 
adopted by these receptors.  
While engineering the human vitamin D receptor (hVDR) to bind and activate in 
response to a novel small molecule ligand, a key characteristic observed was the 
importance of forming and maintaining hydrogen bonding potentials for interactions 
between the receptor and its ligands. The role of H305, H397 and C410 were 
investigated and discussed in Chapter 4. Residues Y143, S237, R274, S278, H305 and 
H397 form important hydrogen bonds with the hVDR’s natural ligand, 1, 25(OH)2D3, 
serving as anchors on each end of the ligand binding pocket (LBP) (Figure 5.1) [5]. The 
activation profiles obtained with the hVDR variants studied in Chapter 4 suggest that the 
end of the LBP consisting of two of these anchoring residues, H305 and H397, and  
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Figure 5.1: The hVDR and 1, 25(OH)2D3,  
hVDR residues (Purple), 1, 25(OH)2D3 (Cyan), hydrogen 
bonds (Red Lines), PDB:1DB1 
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residue C410, tolerates structural variations, as numerous variants with mutations at 
these positions displayed enhanced activity in chemical complementation and 
mammalian cell culture assays. The hVDR’s structure contains two tyrosines located at 
the exact opposite end of the pocket, involved in either direct or indirect contacts with the 
ligand. Thus, the role of these residues at the other end of the pocket was investigated. 
Tyrosines 143 and 147 were two of the residues targeted for mutagenesis in 
hVDR library 2 (a rationally designed library discussed in Chapter 3), and interestingly 
these residues are positioned on the opposite end of the LBP compared to the H305, 
H397 and C410 residues (Figure 5.1). Both residues are within four angstroms of 1, 
25(OH)2D3; Y143 (helix 1) forms a hydrogen bond with the 3β-hydroxyl group of the 
ligand, while Y147 (loop 1-3) shares hydrophobic interactions with the ligand [5]. These 
aromatic residues have also been hypothesized to aid in stabilizing the many loop 
structures in the neighboring region and contributing to the ligand-mediated folding of the 
receptor [6-8]. In an effort to gain further insight into the role of residues at the other 
anchoring end of the ligand binding pocket, mutagenesis was performed to assess the 
tolerance of tyrosines 143 and 147. 
 
5.2 Reversal of the hVDR Ligand Anchors 
Previous protein engineering of the hVDR showed that residues H305 and H397 
changed to tyrosines lead to enhanced activation with lithocholic acid (LCA) and 
cholecalciferol (chole) [9]. Based on these results and those obtained with the C410Y 
variant, where tyrosines on one end of the LBP seem to enhance activity, we chose to 
investigate the role of tyrosines on the other end of the hVDR’s LBP. In previous work by 
Choi et al. and based on performed in-silico docking, different conformational poses 
have been obtained for ligands in the hVDR’s LBP [8, 10]. For example, the positioning 
of the side chain carboxyl group of LCA towards helix 12, and that of 3-keto LCA 
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towards the opposite end of the LBP (~180º rotation) has been observed by Choi et al. 
Similar results have been observed for other receptor-ligand pairs when in-silico docking 
was performed using the program AutoDock Vina, such as the A-ring and side chain of 
cholecalciferol (chole) positioned on opposite ends of the LBP, compared to the 
structure of 1, 25(OH)2D3 (Figure 5.2) [11].  Although the crystal structures of the hVDR 
with LCA, chole and 3-keto LCA are currently unavailable, receptor activation profiles 
obtained via alanine scanning mutational analyses with LCA and 3-keto LCA support 
these docking models [10].  
To comprehensively assess the role of Y143 and Y147, several hypotheses were 
developed and tested. Since mutating H305 and H397 to tyrosines led to enhanced 
activation with LCA and chole, the first question asked was whether modifying Y143 and 
Y147 to histidines would allow wild-type activity with these ligands. Using site-directed 
mutagenesis, residues Y143 and Y147 in the hVDR were mutated to histidines in 
combination with H305Y;H397Y (“reversal of the hVDR ligand anchors”) to determine 
whether the reversal of the residues on opposite ends of the pocket would allow for 
binding and activation (potentially due to binding of a ligand in the LBP in a ~180 º 
rotated conformation). This “reversal” would also provide insight into the tolerance of 
Y143 and Y147, as well as, the impact of secondary shell residues neighboring and 
surrounding these positions. Hence, part of the goal was to determine whether 
maintaining the hydrogen bonding potentials of the anchors on each end of the pocket 
was sufficient for activation, or whether a greater network of molecular interactions exists 
that is involved in ligand binding and activation.  
To further assess the tolerance of residues Y143 and Y147 on their own (double 
variant), these amino acids were changed to histidines via site-directed mutagenesis. 
Each variant was transformed into the PJ69-4A yeast strain along with the coactivator 









































































































growth would be an indication of a small molecule binding and activating the variant 
(ligand activated growth). 
 
   Reversal of the hVDR Ligand Anchors: Results from Chemical Complementation 
When tested in liquid quantitation assays of chemical complementation with 1, 
25(OH)2D3 in adenine selective media (-ALW) and with LCA and chole in histidine 
selective media (SC-HLW + 0.1 mM 3-AT), ligand activated growth was only observed 
for the wild-type hVDR and the H305Y;H397Y variant (Figures 5.3a-c). More specifically, 
the wild-type hVDR and variant H305Y;H397Y shared the same ligand activated growth 
profile with 1,25(OH)2D3 displaying an EC50≈ 5 nM (Figure 5.3a). Ligand activated 
growth was not observed for variants Y143H;Y147H and Y143H;Y147H;H305Y;H397Y 
with this ligand (Figure 5.3a). As expected due to previous results in our lab, 
H305Y;H397Y displayed enhanced ligand activated growth compared to the wild-type 
hVDR when tested with LCA (EC50= 0.4 µM vs. ~EC50> 10 µM) and chole (EC50> 10 µM 
vs. no growth for the wild-type hVDR) (Figures 5.3b and 5.3c). Once again, no ligand 
activated growth was observed for variants Y143H;Y147H and 
Y143H;Y147H;H305Y;H397Y with LCA or chole (Figures 5.3b and 5.3c). Mutating 
tyrosines 143 and 147 to histidines had a detrimental effect on the function of the 
receptor.  
No ligand activated growth was obtained when Y143 and Y147 were changed to 
histidines on their own or in combination with H305Y;H397Y, yet enhanced growth is 
observed for the H305Y;H397Y variant with both LCA and chole. These results are not 
surprising and agree with previously discussed data, once again suggesting that the end 
















































































































tolerates structural changes, in some instances with mutations leading to enhanced 
function of the receptor. These results also suggest that the end of the ligand binding 
pocket consisting of residues Y143 and Y147 is not as tolerant, in terms of allowing 
structural changes without resulting in loss of function. 
 
5.3 Eliminating the Constitutive Activity of A hVDR Variant 
Previous protein engineering of the hVDR showed that residues H305 and H397 
changed to phenylalanines lead to constitutive activation of transcription or constitutive 
activity [9]. Constitutive activity refers to a nuclear receptor (NR) showing growth or 
activation without the presence of an exogenous small molecule ligand. As discussed in 
Chapter 1, helix 12 of most NRs forms the ligand dependent activation function domain 
(AF-2) which serves as a mobile lid over the LBP and is involved in interactions with 
transcriptional coregulators. In some cases, such as that of the constitutive androstane 
receptor (CAR) constitutive activity can result from a fixed active conformation of this 
domain or the binding of an endogenous ligand  [12-15].  
The “reversal of the hVDR ligand anchors” resulted in no ligand activated growth 
due to the detrimental effect of mutating tyrosines 143 and 147 to histidines. To 
determine whether the same effect would be observed for a constitutively active variant, 
residues Y143 and Y147 in the hVDR were mutated to histidines in combination with 
H305F;H397F via site-directed mutagenesis. Each variant was transformed into the 
PJ69-4A yeast strain along with the coactivator plasmid (pGAD10BAACTR) and tested 
using chemical complementation. 
 




  Eliminating the Constitutive Activity of A hVDR Variant: Results from Chemical   
 Complementation 
When tested in liquid quantitation assays of chemical complementation with LCA 
and chole in histidine selective media (SC-HLW + 0.1 mM 3-AT), constitutive activity was 
observed for variants H305F;H397F and Y143H;H305F;H397F (Figures 5.4a and 5.4b). 
Interestingly, the wild-type hVDR and variant Y147H;H305F;H397F shared similar ligand 
activated growth profiles with LCA  with an EC50> 10 µM (Figure 5.4a). 
Y147H;H305F;H397F also displayed ligand activated growth with chole with an EC50> 10 
µM. Due to the expense of the hVDR’s natural ligand, 1, 25(OH)2D3, only LCA and 
chole were used to collect this set of data. 
As expected, mutating both tyrosines, 143 and 147, to histidines in combination 
with H305F;H397F (resulting in variant Y143H;Y147H;H305F;H397F) had a detrimental 
effect on the function of the receptor. As with the variants for the “reversal of the hVDR 
ligand anchors”, no ligand activated growth was observed for 
Y143H;Y147H;H305F;H397F. However, when Y143H and Y147H were introduced into 
H305F;H397F individually, the results obtained were quite surprising. Y147H seems to 
reverse the constitutive activity observed with H305F;H397F, such that the variant 
displays ligand activated growth with LCA and chole. Introducing Y143H however does 
not have the same effect, as constitutive activity is still observed. This set of data 
suggests that although mutations at the end of the ligand binding pocket consisting of 
residues Y143 and Y147 seem to be detrimental to the function of the receptor, thus far 
position Y147 is possibly less tolerant than Y143 as the presence of Y147H in 











Figure 5.4: Eliminating the Constitutive Activity of A hVDR Variant: 
hVDR Variants in Chemical Complementation.   
Histidine selective media with (a) LCA and (b) chole
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5.4 Mutational Tolerance of hVDR Residues Y143 and Y147 
Residues Y143 and Y147 are within four angstroms of 1, 25(OH)2D3. Y143 
forms a hydrogen bond with the ligand, while Y147 is involved in hydrophobic  
interactions. In previous work, mutating Y143 to alanine has been shown to drastically 
reduce activity, while mutating Y147 to alanine nearly eliminates activity [7, 8]. 
Additionally, Y143A has resulted in large effects on ligand binding, while Y147A has had 
a larger influence on receptor activity [7]. Tyrosines 143 and 147 are also known to be 
part of an important cluster of aromatic residues in the hVDR’s  ligand binding pocket 
(LBP) consisting of residues F150, W286 and Y295 (Figure 5.5) [7, 8]. These aromatic 
residues have been hypothesized to aid in stabilizing the many loop structures in the 
region and contributing to the ligand-mediated folding of the receptor [6-8]. 
To explore these residues beyond alanine mutagenesis and gain a better 
understanding of the mutational tolerance at these positions, residues Y143 and Y147 
were changed to amino acids of varying properties via site-directed mutagenesis. The 
amino acids histidine, phenylalanine, lysine, tryptophan, leucine, and serine were 
chosen, as they exhibit diverse characteristics in terms of residue shape, size and 
polarity. Each single and double (Y143 and Y147 positions simultaneously mutated to 
the same amino acid) variant was transformed into the PJ69-4A yeast strain along with 
the coactivator plasmid (pGAD10BAACTR) and tested using chemical complementation. 
A subset of variants was also tested in mammalian cell culture assays. Overall, we 
expected variants with amino acids of similar shape and size to tyrosine at the Y143 and 
Y147 positions to exhibit activation profiles similar to that of the wild-type hVDR. For 
example, variants Y143F and Y147F were hypothesized to display better activity than 
Y143S and Y147S despite the fact that both tyrosine and serine have a hydroxyl group. 
Previous work in our lab showed that at positions 305 and 397, the volume of the 
residue was critical in maintaining the function of the receptor with the natural ligand [9].  
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Figure 5.5: hVDR Residues Y143 and Y147.  
Tyrosines 143 and 147 are part of an important cluster of aromatic residues in 
the hVDR’s ligand binding pocket. hVDR residues (Purple), 1, 25(OH)2D3 
(Cyan), PDB:1DB1 
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The same concept may apply to the residues at the other end of the pocket. 
      
Mutational Tolerance of hVDR Residues Y143 and Y147: Results for Single and  
Double Variants in Chemical Complementation 
When tested in liquid quantitation assays of chemical complementation with 
1,25(OH)2D3 in adenine selective media (-ALW) and with LCA and chole in histidine 
selective media (SC-HLW + 0.1 mM 3-AT), ligand activated growth was observed for 
only a few of the single and double Y143 and Y147 variants (Figures 5.6a-c, 5.7a-c and 
5.8). When tested with 1,25(OH)2D3, variants Y143H, F and W showed a slight (~10-
fold) decrease in sensitivity compared to the wild-type hVDR with an ~EC50> 100 nM (vs. 
EC50= 18 nM) (Figure 5.6a). Variants Y147H, F and W showed a similar behavior with 
1,25(OH)2D3, displaying an ~EC50> 100 nM (Figure 5.7a). Only one of the double 
variants, Y143F;Y147F, exhibited ligand activated growth with 1,25(OH)2D3 with an 
~EC50> 100 nM (Figure 5.8). 
As expected, ligand activated growth was observed for the wild-type hVDR with 
LCA at 10 µM (Figures 5.6b and 5.7b). For several of the single Y143 and Y147 variants, 
very little ligand activated growth was obtained with LCA at 10 µM (Figures 5.6b and 
5.7b). No growth was obtained for any of the variants with chole (Figures 5.6c and 5.7c).  
Thus far only bulky (residue volumes: tyrosine 193.6 Å3, histidine 153.2 Å3, 
phenylalanine 189.9 Å3, and tryptophan 227.8 Å3) amino acids also consisting of an 
aromatic ring have contributed to ligand activated growth with hVDR’s natural ligand in 
chemical complementation [16]. Considering that tryptophan has the largest volume 
among all amino acids, we did not expect the ligand activated growth displayed by the 
Y143W and Y147W variants. However, mutating Y143 and Y147 simultaneously may 














































































































































































































































Figure 5.8: Mutational Tolerance of hVDR Residues Y143 and Y147: 
Double Variants in Chemical Complementation.  
Adenine selective media with 1, 25(OH)2D3
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ligand activated growth was only observed for one of  the double variants 
(Y143F;Y147F). This was not surprising, as phenylalanine is the amino acid most similar 
in properties, shape and size, to tyrosine. 
  
 Mutational Tolerance of hVDR Residues Y143 and Y147: Results for Single and  
 Double Variants in Mammalian Cell Culture Assays 
To determine whether the results obtained in yeast with the hVDR Y143 and 
Y147 variants were consistent in mammalian cell culture assays, mammalian expression 
plasmids (pCMX, with a cytomegalovirus promoter) containing a subset of the variants 
with interesting ligand activated growth profiles were transfected into human embryonic 
kidney 293T (HEK 293T) cells along with the p17*4TATALuc (containing a luciferase 
gene under the control of four Gal4 response elements) reporter plasmid (as described 
by Taylor et al.) [17]. Cell culture assays were performed with 1, 25(OH)2D3, where 
luciferase activity would be an indication of a small molecule binding and activating the 
variant. 
When tested with 1,25(OH)2D3, the overall trend observed for the Y143 and 
Y147 single variants was consistent with the results obtained in chemical 
complementation. An EC50= 5 nM and a 97-fold activation was observed for the wild-type 
hVDR, which displayed the best activity compared to all the variants tested. Residue 
Y143 exhibited preference for phenylalanine (EC50= 6 nM and 79-fold activation), 
followed by tryptophan (EC50= 50 nM and 161-fold activation) and histidine (EC50= 76 nM 
and 130-fold activation) (Figure 5.9 and Table 5.1). Residue Y147 exhibited preference 
for phenylalanine (EC50= 16 nM and 131-fold activation), followed by histidine (EC50= 47 
nM and 69-fold activation) and tryptophan (EC50= 118 nM and 101-fold activation) 





Figure 5.9: Mutational Tolerance of hVDR Residue Y143:  
Single Variants in Mammalian Cell Culture Assay with 1, 25(OH)2D3 
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 Figure 5.10: Mutational Tolerance of hVDR Residue Y147:  
Single Variants in Mammalian Cell Culture Assay with 1, 25(OH)2D3 
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displayed activity with 1,25(OH)2D3, but at much higher concentrations 
 (Figures 5.9 and 5.10, and Table 1). In agreement with the results obtained in yeast, 
mutating Y143 and Y147 simultaneously to the same amino acid proved to be 
detrimental in all cases suggesting that a disruption of residue packing and/or important 
interactions within the ligand binding pocket was caused (Figure 5.11 and Table 5.1). 
 Overall, the results obtained in yeast and mammalian cell culture assays for the 
hVDR Y143 and Y147 single and double variants demonstrate that most changes at 
these positions are detrimental to the function of the receptor. Once again, this data 
supports the hypothesis that this end of the hVDR’s ligand binding pocket is less tolerant 
of structural variations, compared to the opposite end consisting of residues H305, H397 
and C410. None of the mutations studied resulted in enhanced receptor function, 
however the conservative change to phenylalanine and semi-conservative changes to 
histidine and tryptophan resulted in activation similar to that of the wild-type hVDR. This 
is probably due to the presence of an aromatic group which might continue to interact 
favorably with the important cluster of aromatic residues Y143 and Y147 are a part of 
(Figure 5.5). The other amino acids tested may disrupt or not satisfy these interactions, 
resulting in little to no hVDR activation. These results suggest that maintaining proper 
residue packing within the ligand binding pocket may be more important than 
maintaining the hydrogen bonding interactions, as suggested by previous research [18].  
 
5.5 Summary 
Previously discussed variants (Chapter 4) with enhanced activity compared to 
the wild-type human vitamin D receptor have indicated that the end of the receptor’s 
ligand binding pocket (LBP) consisting of residues H305, H397 and C410, tolerates 
mutations and can compensate for structural variations. Tyrosines 143 and 147 were 
two of the residues targeted for mutagenesis in one of the rationally designed  
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Figure 5.11: Mutational Tolerance of hVDR Residues Y143 and Y147:  
Double Variants in Mammalian Cell Culture Assay with 1, 25(OH)2D3 
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libraries discussed in Chapter 3, and interestingly these residues are positioned on the 
opposite end of the hVDR’s LBP (Figure 5.1). In this work we explored the end of the 
ligand binding pocket consisting of residues Y143 and Y147, using mutagenesis to gain 
insight on the role and mutational tolerance of these residues. Overall, most changes at 
these positions proved to be detrimental to the function of the receptor supporting the 
hypothesis that this end of the LBP is less tolerant of structural changes. 
This work consisted of testing double variants where residues Y143 and Y147 
were simultaneously changed to the same amino acid, while future work can focus on 
mutating these residues to different amino acids. This will help determine whether other 
combinations of amino acid properties work well together at these positions. Additional 
structural studies on the important aromatic cluster formed by residues Y143, Y147, 
F150, W286 and Y295 would also be useful for protein engineering, providing insight 
into how this cluster provides stability for the rest of the protein structure and how 
important each position is in contributing towards this role.  
 
5.6 Materials and Methods 
Ligands 
1α, 25-dihydroxyvitamin D3, lithocholic acid and cholecalciferol were purchased 
from BIOMOL (Plymouth Meeting, PA), MP Biomedicals, LLC (Solon, OH) and Sigma-
Aldrich (St. Louis, MO), respectively. 10 mM stocks of LCA and chole, and a 13.3 µM 
stock of 1α,25-dihydroxyvitamin D3 were made with 80 % ethanol: 20 % dimethyl 
sulfoxide (DMSO) and stored at 4 °C. 
 
In-silico Docking of Wild-type hVDR 
  The atomic coordinates of the crystal structure of the hVDR ligand binding 
domain (165-215) were retrieved from the Research Collaboratory for Structural 
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Bioinformatics (RCSB) Protein Data Bank (PDB) (PDB ID: 1DB1) [5, 19]. The structure 
was prepared for docking using the UCSF CHIMERA-interactive molecular graphics 
program by: (1) removing the ligand and water molecules, (2) adding polar hydrogens, 
and (3) assigning Gasteiger charges [20]. The three-dimensional structure of each ligand 
was constructed and minimized using ChemBioDraw Ultra 11.0 and ChemBio3D Ultra 
11.0 (Cambridge Soft, USA) [21]. AutoDockTools was used to add Gasteiger charges to 
each ligand structure, setting the partial charge property of each atom. Docking 
simulations were performed using AutoDock Vina with default parameters, such that the 
protein was held rigid and the ligand was allowed free rotation [11]. The receptor-ligand 
poses of lowest free energy of binding were analyzed further. 
 
Site-Directed Mutagenesis 
Mutations were introduced into the yeast expression plasmid, pGBDhVDR, using 
PCR (Stratagene, Santa Clara, CA) and the corresponding mutagenic primers (Operon, 
Huntsville, AL).  All plasmids were purified using the QIAprep® Spin Miniprep Kit 
(Qiagen, Valencia, CA) and sequenced for confirmation (Operon, Huntsville, AL).  
 
Yeast Transformation Using the PJ69-4A Strain 
 Using the 1x TRAFCO yeast transformation protocol, ~500 ng of the yeast 
expression plasmids, pGBDhVDR (containing the Gal4 DBD fused to the full-length 
hVDR with the corresponding mutation(s) and a tryptophan marker) and 
pGAD10BAACTR (containing the Gal4 AD fused to ACTR and a leucine marker), were 
co-transformed into the yeast strain PJ69-4A [22]. Transformants were plated onto non-
selective synthetic complete agar plates lacking leucine and tryptophan (SC-LW) to 
select for both fusion plasmids. Plates were incubated at 30 ºC for 3-4 days.  
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Liquid Quantitation Assays of Chemical Complementation in Yeast 
Transformants obtained from the yeast transformation were grown overnight in 
non-selective SC-LW media, at 30 ºC with shaking at 300 rpm. A 4:1 ratio of selective 
media (SC-ALW or SC-HLW) with and without ligand at varying concentrations: cells 
(yeast resuspended in water) were aliquoted into 96-well plates. Plates were then 
incubated at 30 ºC with shaking at 170 rpm for 48 hours, with optical density readings at 
a wavelength of 630 nm (OD630) taken at 0, 24 and 48 hours. All data points represent 
the mean of at least duplicate experiments and the bars indicate standard deviation. The 
lowest ligand concentration data points for all plots contain no ligand. EC50 values were 
calculated using GraphPad Prism and a non-linear regression extrapolation. 
 
Construction of Mammalian Expression Plasmids  
The Gal4 DBD fused to the hVDR for each of the Y143 and Y147 single and 
double variants was amplified from the respective pGBD yeast expression plasmid via 
PCR (55 ºC as the annealing temperature) using 125 ng of the following primers: 5’-tcc 
ccg cgg atg aag cta ctg tct tct atc gaa caa g-3’ and 5’- aag gaa aaa agc ggc cgc tca gga 
gat ctc att gcc aaa ca-3’ (Operon, Huntsville, AL). The underlined sequences denote 
SacII and NotI restriction sites, respectively. The fusion constructs and mammalian 
expression plasmid, pCMX (discussed in Chapter 3), were digested with SacII and NotI, 
ligated, and transformed into Z-competent™ XL-1 Blue Escherichia coli (E.coli) cells 
(Zymo, Orange, CA). The resulting plasmids were purified using the QIAprep® Spin 






Mammalian Cell Culture Assays 
Human embryonic kidney 293T cells (HEK 293T, ATCC, USA) were transfected 
with the pCMX mammalian expression plasmids discussed above, along with the 
p17*4TATAluc and pCMXβ-gal reporter plasmids (discussed in Chapter 3) as described 
by Taylor et al., using Lipofectamine 2000 (Invitrogen, Carlsbad, CA) as the cationic lipid 
[17]. Cells were harvested ~36-48 hours after the addition of ligand at varying 
concentrations, and analyzed for luciferase and β-galactosidase activity. All data points 
represent the mean of triplicate experiments normalized against β-galactosidase activity 
and the bars indicate standard deviation. The lowest ligand concentration data points for 
all plots contain no ligand. EC50 values were calculated using GraphPad Prism and a 
non-linear regression extrapolation. Fold activations were calculated by dividing the 
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